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Abstract
Valosin-containing protein (VCP) is a highly conserved molecular chaperone that regulates a wide array of
essential cellular processes. Mutations in VCP are causative of degenerative disease that can affect muscle,
brain and bone. Despite VCP being implicated in many major pathways in the cell, the mechanism of disease
pathogenesis is unknown. To gain insight into the degeneration associated with mutations in VCP, we
developed and characterized a Drosophila model of disease that recapitulated VCP mutation-dependent
toxicity. VCP is involved in a diverse array of activities, many of which we may not know. Therefore we
employed an unbiased genetic screening method that has the potential to uncover unanticipated pathways
affected in the disease. Using this approach, we identified four proteins that dominantly suppressed
degeneration; one of which was Ube4b, one of the many known ancillary proteins that bind to VCP and
determine its function. The three remaining dominant modifiers identified were all RNA-binding proteins
including TBPH, the Drosophila orthologue of TAR (trans-activating response region) DNA-binding protein
(TDP-43). TDP-43 has been identified as a major component of the ubiquitinated inclusions characteristic of
an emerging spectrum of proteinopathies, including degeneration associated with VCP mutations.
Redistribution of TDP-43 from the nucleus to the cytoplasm has been demonstrated in these proteinopathies
but the significance of this was unknown. Here we demonstrated that TDP-43 and VCP interact genetically
and disease-causing VCP mutations led to redistribution of TDP-43 to the cytoplasm in vitro and in vivo,
replicating the major pathology observed in TDP-43 proteinopathies. Furthermore, we demonstrated that
TDP-43 redistribution is sufficient to induce cytotoxicity. Together our results show that degeneration
associated with VCP mutations is mediated, in part, by toxic gain of function of TDP-43 in the cytoplasm
where its redistribution is possibly due to the altered binding repertoire of VCP. This work acts to further our
understanding of the pathogenic mechanism of, not only VCP-related disease but also a broad array of
TDP-43 proteinopathies that include frontotemporal dementia, inclusion body myopathies and amyotrophic
lateral sclerosis.
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ABSTRACT 
 
THE BASIS OF VCP-MEDIATED DEGENERATION: INSIGHTS FROM A DROSOPHILA 
MODEL OF DISEASE 
 
Gillian P. Ritson 
Supervisor: J. Paul Taylor 
 
 Valosin-containing protein (VCP) is a highly conserved molecular chaperone that 
regulates a wide array of essential cellular processes. Mutations in VCP are causative of 
degenerative disease that can affect muscle, brain and bone. Despite VCP being 
implicated in many major pathways in the cell, the mechanism of disease pathogenesis 
is unknown. To gain insight into the degeneration associated with mutations in VCP, we 
developed and characterized a Drosophila model of disease that recapitulated VCP 
mutation-dependent toxicity. VCP is involved in a diverse array of activities, many of 
which we may not know. Therefore we employed an unbiased genetic screening 
method that has the potential to uncover unanticipated pathways affected in the 
disease. Using this approach, we identified four proteins that dominantly suppressed 
degeneration; one of which was Ube4b, one of the many known ancillary proteins that 
bind to VCP and determine its function. The three remaining dominant modifiers 
identified were all RNA-binding proteins including TBPH, the Drosophila orthologue of 
TAR (trans-activating response region) DNA-binding protein (TDP-43). TDP-43 has been 
identified as a major component of the ubiquitinated inclusions characteristic of an 
iv 
 
emerging spectrum of proteinopathies, including degeneration associated with VCP 
mutations. Redistribution of TDP-43 from the nucleus to the cytoplasm has been 
demonstrated in these proteinopathies but the significance of this was unknown. Here 
we demonstrated that TDP-43 and VCP interact genetically and disease-causing VCP 
mutations led to redistribution of TDP-43 to the cytoplasm in vitro and in vivo, 
replicating the major pathology observed in TDP-43 proteinopathies. Furthermore, we 
demonstrated that TDP-43 redistribution is sufficient to induce cytotoxicity. Together 
our results show that degeneration associated with VCP mutations is mediated, in part, 
by toxic gain of function of TDP-43 in the cytoplasm where its redistribution is possibly 
due to the altered binding repertoire of VCP. This work acts to further our 
understanding of the pathogenic mechanism of, not only VCP-related disease but also a 
broad array of TDP-43 proteinopathies that include frontotemporal dementia, inclusion 
body myopathies and amyotrophic lateral sclerosis. 
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CHAPTER 1: INTRODUCTION  
2 
Mutations in VCP cause a degenerative disorder of muscle, brain and bone 
Inclusion body myopathy associated with Paget’s disease of bone and 
frontotemporal dementia (IBMPFD; MIM605382) is a rare, complex and ultimately lethal 
autosomal dominant disorder. Patients were considered to have IBMPFD if they 
displayed two or more of the clinical triad. However, this definition preceded the 
identification of the underlying genetic cause. A genome-wide screen of four large 
families showed linkage of IBMPFD to a 1.08–6.46 cM critical interval on chromosome 
9p13.3-12 (Kovach et al. 2001). Subsequently, using a candidate gene approach, six 
mutations were identified in the gene valosin-containing protein (VCP) in thirteen North 
American families with IBMPFD (Watts 
et al. 2004). Today, it is known that VCP-
related disease may manifest in muscle, 
brain, bone, or a combination thereof 
(Fig 1.1).  
Paget’s disease is a chronic focal 
skeletal disease present in roughly 45% 
of IBMPFD patients. The primary 
pathologic abnormality manifests as 
increased bone resorption and formation that result in abundant new bone, which is 
highly disorganized and of poor quality, typically in the spine, pelvis, scapulae and skull. 
This can manifest as reduced height, pathologic fractures or hearing loss due to cranial 
bone deformity. The imbalance of bone turnover results from the hyperactivity of the 
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osteoclasts, which break down bone (Reddy 2006). Histological analysis reveals 
abnormally large, multinucleated osteoclasts with nuclear inclusions of paired helical 
filaments similar to that seen in IBM (Kimonis et al. 2008).  Immunohistochemical 
analysis of these filamentous inclusions has yet to be reported. At 45 years of age in 
IBMPFD, the average age of onset of bone deformity and enlargement is earlier than 
sporadic Paget’s disease (Lucas et al. 2005). The age of onset is similar to the slowly 
progressive distal and proximal muscle weakness seen in IBMPFD patients with 
myopathy. Patients with inclusion body myopathy (IBM) exhibit an abnormal gait and 
show an inability to raise the arms; difficulty climbing stairs and mild weakness of the 
hands. Clinically, patients display a generalized reduction or absence of tendon reflexes, 
normal nerve conduction, and myopathic electromyogram. The serum creatine 
phosphokinase levels are normal to slightly elevated (Kimonis et al. 2008).  Muscle 
biopsies in affected individuals show the presence of atrophic and hypertrophic fibers, 
rimmed vacuoles and cytoplasmic inclusion bodies. Immunohistochemical analysss has 
shown that pathological sarcoplasmic accumulation of TDP-43 is present in about 23% 
of muscle fibers; similar to that seen in sporadic and other familial forms of IBM 
(Salajegheh et al. 2009). In advanced cases, severe degeneration and fatty replacement 
of muscle fibers can be noted.  
The central nervous system involvement (CNS) in IBMPFD typically presents as 
dementia, although there are reports of Parkinsonism and motor neuron disease. The 
presentation of CNS components is later than both the IBM and Paget’s disease with a 
mean age of 55 years at onset and is reported in only 38% of IBMPFD cases (Fig 1.1) 
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(Kovach et al. 2001; Kimonis and Watts 2005). The dementia associated with IBMPFD is 
typical of frontotemporal dementia (FTD) (Lund and Manchester Groups (1994; 
McKhann et al. 2001) and is characterized by language and/or behavioral dysfunction 
with relative preservation of memory which serves as a discriminator between FTD and 
Alzheimer’s disease (AD) (Kimonis et al. 2000; Kovach et al. 2001; Forman et al. 2006). 
This is matched by cerebral atrophy in the frontal and anterior temporal lobes of the 
brain rather than the hippocampal, posterior temporal and parietal effects of AD. 
Histologically, patients display a novel pattern of ubiquitin pathology distinct from other 
forms of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U). 
IBMPFD neuropathology is characterized by abundant ubiquitin-positive neuronal 
intranuclear inclusions and dystrophic neurites in the neocortex. Inclusions rarely stain 
against VCP antibodies and there is no biochemical alteration of the VCP protein 
(Forman et al. 2006). Single case reports have also reported the presence of a dilated 
cardiomyopathy (Hubbers et al. 2007) and hepatic fibrosis (Guyant-Marechal et al. 
2006), although it is unclear if these disorders are part of the clinical spectrum of VCP-
related disease. Indeed the classification of IBMPFD is currently evolving. Other reports 
are soon to be published that mutations in VCP cause ALS, with further data indicating 
that mutations may also cause Parkinsonism. As more patients with a brain, bone or 
muscle disease are genotyped, the current definition of VCP-related disease will be 
expanded.  
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Valosin-containing protein is an AAA ATPase with many functions 
Valosin containing protein (VCP), also known as p97, and its homologues ter94 
(Drosophila) and cdc48p (S. cerevisiae) are part of the AAA family (ATPases associated 
with various cellular activities) (Table 1.1). This diverse family of enzymes is associated 
with a wide range of cellular processes including proteolysis, DNA repair and membrane 
fusion that it carries out in an ATP-dependent manner (Ogura and Wilkinson 2001). The 
ATPase domain is characterized by a conserved sequence of 200-250 residues (Fig 1.2). 
The type II AAA ATPase family, of which VCP is a member, contains two of these ATPase 
domains, referred to as D1 and D2. By electron microscopy, VCP forms a hexameric 
structure composed of dual stacking rings formed by the D1 and D2 ATPase modules 
(Rouiller et al. 2000; Zhang et al. 2000; Song et al. 2003; Wang et al. 2003). The D1 
domain is primarily responsible for VCP hexamerization but this molecular assembly is 
not dependent on nucleotide binding 
(Zhang et al. 2000; Wang et al. 2003; 
Wang et al. 2003)(Fig 1.2B). The 
ATPase activity conferred by the D2 
domain is essential for VCP’s function 
as a molecular chaperone in a 
plethora of distinct cellular processes 
(Song et al. 2003; Esaki and Ogura 
2010).  
6 
VCP coordinates a number of ubiquitin-regulated processes through its basic 
function as a molecular segregase that utilizes ATP-powered conformational changes in 
the assembly and disassembly of macromolecular machineries (Halawani and Latterich 
2006; Jentsch and Rumpf 2007). VCP is essential to some aspects of ubiquitin-
dependent degradation including endoplasmic reticulum-associated degradation 
(ERAD), degradation of some cytosolic proteins by the ubiquitin-fusion domain (UFD) 
pathway, and rapid degradation of nascent peptides during heat shock as well as 
autophagosomes maturation in autophagy (Wojcik et al. 2006; Ballar and Fang 2008; 
Medicherla and Goldberg 2008; Tresse et al. 2010). VCP also is integral to some 
nonproteolytic aspects of ubiquitin signaling, including chromatin decondensation 
following mitosis (Ramadan et al. 2007), nuclear envelope formation (Hetzer et al. 2001) 
and homotypic membrane fusion during biogenesis of the ER and Golgi apparatus 
(Uchiyama et al. 2002). 
Additional, albeit less conserved, domains are the C-terminal and substrate-
binding N-domain (Zhang et al. 2000; DeLaBarre and Brunger 2003). The C domain is 
poorly characterized, but this region includes the major tyrosine phosphorylation site 
implicated in the regulation of endoplasmic reticulum (ER assembly) and cell cycle-
dependent nuclear localization of VCP (Egerton and Samelson 1994; Madeo et al. 1998; 
Lavoie et al. 2000).  
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VCP interacts with a wide range of adaptor proteins 
The diversity in VCP/p97 activities reflects its ability to interact with a diverse 
array of cofactor proteins. The majority of these adaptor complexes are formed via the 
N-terminal domain, including the well characterized adaptors p47 and the Ufd-1-Npl4 
complex (Dreveny et al. 2004). The VCP-p47 complex is required for proper post-mitotic 
assembly of Golgi stacks as well as fusion of the ER membrane (Uchiyama et al. 2002; 
Uchiyama et al. 2003). In addition to this homotypic membrane fusion role, VCP-p47 has 
been implicated in protein degradation through the ubiquitin proteasome system (UPS), 
possibly by aiding in the delivery of substrates to the proteasome (Hartmann-Petersen 
et al. 2004; Schuberth et al. 2004). VCP is essential for ERAD, a pathway in which 
defective or abnormally folded and short-lived ER proteins are degraded (Romisch 
2005). VCP’s participation in ERAD is dependent on its binding partners Ufd1 and Npl4 
(Ye et al. 2001; Braun et al. 2002; Jarosch et al. 2002; Rabinovich et al. 2002). 
Specifically, substrates destined for proteasomal degradation are retrotranslocated 
from the ER lumen to the cytosolic face of the ER where they are bound by the 
VCP/Ufd1-Npl4 complex (Ye et al. 2001; Jarosch et al. 2002; Ye et al. 2003; Ye et al. 
2004). The ERAD substrates are subsequently ubiquitinated and transferred to the 
proteasome for degradation (Rape et al. 2001; Meusser et al. 2005). VCP’s role within 
the cell is not confined to the cytoplasm and its organelles. In addition to a role in 
maintaining the nuclear membrane (as an extension of VCP-p47’s homotypic membrane 
fusion role) (Hetzer et al. 2001), VCP also has functions within the nucleus. For example, 
VCP binds directly to the N-terminal Ube4b portion of the chimeric protein Wallerian 
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degeneration slow (WldS). This protein is known to delay injury-induced axonal 
degeneration partly through its VCP-dependent re-positioning into functional nuclear 
foci (Wilbrey et al. 2008). Furthermore, VCP plays an important role in the signal-
dependent release of the genome maintenance Werner helicase protein (WRNp) from 
its nucleolar sequestration site through an ATP-dependent interaction (Partridge et al. 
2003; Indig et al. 2004). These roles, though in different subcellular compartments, 
consistently demonstrate a role of VCP in forming an adaptor complex, binding 
substrates and then untethering them from their binding partners. 
 The functions of VCP and its adaptor complexes described here are only a few of 
the better characterized functions of VCP. It is clear though that the binding of the 
substrate to VCP is how the function of VCP is determined and explains how a protein 
can participate in such diverse cellular functions in all compartments of the cell. Despite 
knowing the identity of over 40 adaptors, the association between VCP and such a wide 
range of proteins is still poorly understood. Interactions such as of VCP and UBX 
(ubiquitin regulatory X) domain of p47, and the UBD (ubiquitin binding domain) of Npl4 
have been structurally characterized. Details are also emerging about the interactions of 
several short VCP-interacting motifs, such as VBM (VCP-binding motif), VIM (VCP-
interacting motif) and SHP. Many of these domains are known to be shared among 
adaptors, despite having different functions, implying that currently unidentified 
proteins that possess the same VCP-binding motif might provide a novel function for 
VCP (Yeung et al. 2008; Ewens et al. 2010).  For example, p37 binds VCP through a UBX 
domain similar to p47, but instead of a post-mitotic function, VCP-p37 functions in Golgi 
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and ER biogenesis during interphase and at the end of mitosis (Uchiyama et al. 2006). It 
is accepted that the full complement of VCP’s binding partners has yet to be 
determined, possibly implicating VCP in new cellular functions. There are many avenues 
of research underway to understand the process of VCP’s association with adaptors and 
how this could relate to disease. 
 
Disease-causing mutations localize to N-D1 domain interface 
To date, a total of 15 VCP gene mutations have been reported in more than 20 
kindred from North America, Germany, France, Austria, Belgium, Italy and Australia 
(Kimonis et al. 2008; Djamshidian et 
al. 2009; Kumar et al. 2010). The 
most common mutation position 
(155) yields four of the disease-
causing mutations (R155H:C:P:L). 
The mutation that is associated with 
the most severe clinical course is 
A232E and disrupts a region in D1 
(Watts et al. 2004). Interestingly, 
the amino acids affected by the 
disease-causing mutations are highly conserved across species (Table 1.1). It is unknown 
how mutations in VCP cause disease but recent studies have shed light on how they 
affect the structure. The majority of the causative mutations in VCP localize to the 
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interface of the N- and D1-domains (Fig 1.3). This causes conformational changes that 
result from impaired communication between the D1 and N domains and indirectly 
influence the nucleotide binding pocket in D1 (Fernandez-Saiz and Buchberger 2010). 
The most profound result of this appears to be a change in the relative affinity for ATP 
and ADP. IBMPFD mutations, R155P and A232E in VCP show an increase in ATPase 
activity and increased sensitivity to heat-induced upregulation in ATPase activity 
(Halawani et al. 2009). The effect of this on VCP’s functions and how it underlies the 
mechanism of pathogenesis in biological systems is unknown and warrants further 
investigation. 
 
VCP is implicated in diseases other than IBMPFD 
Prior to the recognition that mutations in VCP were causative of IBMPFD, VCP 
was implicated as playing a role in disease. VCP protein has been found overexpressed 
in gastric, colon, pancreatic and hepatocellular cancers (Vij 2008). Furthermore, RNA 
interference or overexpression of ATPase-deficient VCP in tumor cell lines has been 
shown to cause cell death (Kobayashi et al. 2002; Wojcik et al. 2004). Analagous to VCP’s 
connection to FTD, VCP has been detected in a small proportion of the disease-defining 
inclusions of a broad array of neurodegenerative diseases. These include senile plaques 
in Alzheimer’s disease, Lewy bodies in Parkinson’s disease, neuronal intranuclear 
inclusions in polyglutamine diseases and ubiquitin-positive inclusions in amyotrphic 
lateral sclerosis (ALS) (Hirabayashi et al. 2001; Mizuno et al. 2003; Ishigaki et al. 2004). A 
more direct role for VCP in the pathogenesis of neurodegenerative disease is derived 
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from studies in Drosophila melanogaster and Caenorhabditis elegans (Higashiyama et al. 
2002; Yamanaka et al. 2004). An unbiased genetic screen in Drosophila identified null 
mutations in TER94 as a suppressor of polyglutamine induced toxicity (Higashiyama et 
al. 2002). Seemingly in contrast with these results, over-expression of human VCP in the 
fly suppressed neurotoxicity associated with polyglutamine-expanded ataxin-3 
(Boeddrich et al. 2006). In C.elegans, overexpression of C41C4.8 and C06A1.1, worm 
homologs of human VCP, suppresses the formation of aggregates resulting from 
expanded polyglutamine repeats, but the impact on neurodegeneration was not 
reported (Yamanaka et al. 2004). 
 Of course, a role for VCP in human neurodegenerative disease has now been 
firmly established by the identification of causative mutations in IBMPFD (Watts et al. 
2004). How mutations in VCP cause disease and what role VCP plays in the pathogenesis 
of other diseases is unknown, though much could be learned from studying the 
similarities (and differences) between them and other related disorders.  
 
TDP-43 is a multifunctional protein implicated in many diseases 
TAR DNA binding protein 43 (TDP-43) was recently identified as a major disease 
protein in the ubiquitinated inclusions characteristic of both sporadic and familial FTLD-
U and ALS (Neumann et al. 2006). TDP-43 is a 414 amino acid nuclear protein encoded 
by the TARDBP gene on chromosome 1. The functions of TDP-43 are not yet fully 
understood. TARDBP was first identified as a gene encoding a 43kDa protein that bound 
to the transactivating responsive DNA sequence of HIV1 (human immunodeficiency 
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virus type 1)(Ou et al. 1995). Its role was further extended when TDP-43 was shown to 
be involved in the splicing of the CFTR and apoplioprotein A-II genes (Buratti et al. 2001; 
Mercado et al. 2005). It contains 2 RNA-recognition motifs, nuclear localization and 
nuclear export sequences, and a glycine-rich carboxy terminal region that may be 
required for the exon skipping and splicing inhibitory activity as well as binding to 
nuclear proteins (Fig 1.4). This is consistent with the finding that the C-terminus binds 
several proteins in the hnRNP family (heterogeneous nuclear ribonucleoprotein family 
as well as being classed as an hnRNP itself [reviewed in (Geser et al. 2010)]. Other 
reported functions of TDP-43 include: acting as a scaffold for nuclear bodies through 
interaction with survival motor 
neuron protein (Wang et al. 
2002), stabilization of low 
molecular weight neurofilament 
protein mRNA through a direct 
interaction with its 3’ 
untranslated region (Strong et 
al. 2007) and microRNA biogenesis (Gregory et al. 2004). Recent studies have focused 
on how the predominantly nuclear TDP-43 undergoes nucleocytoplasmic shuttling and 
associates with translation machinery in the cytoplasm (Ayala et al. 2008; Wang et al. 
2008; Freibaum et al. 2010). Thus the physiological functions of TDP-43 are diverse 
though incompletely characterized but likely involve the regulation of multiple biological 
processes through binding to DNA, RNA and other proteins. 
13 
Pathological TDP-43 in ALS and FTLD-U was described as hyperphosphorylated, 
ubiquitinated, and cleaved to generate C-terminal fragments and was recovered only 
from affected central nervous system 
regions, including hippocampus, 
neocortex and spinal cord (Neumann 
et al. 2006). Since the initial discovery 
of TDP-43 pathology, not only has its 
pathological signature been found to 
be more abundant in the brain than 
initially characterized (Brandmeir et 
al. 2008; McClusky et al. 2009), but there has been a whole spectrum of related 
proteinopathies classified based upon ubiquitin-positive TDP-43 deposition. These 
diseases are classed as those ranging from TDP-43 pathology in 10-30% of cases 
(including normal aging, superoxide dismutase-1 linked amyotrophic lateral sclerosis, 
and multiple system atrophy), those where pathological TDP-43 is secondary to the 
defining pathology (Alzheimer’s disease, Parkinson’s disease and Huntington’s disease) 
to those with major TDP-43 status where in 100% of cases, ubiquitin-positive TDP-43 
deposition is the primary defining pathology (Geser et al. 2009). This latter class is 
composed of a clinicopathological spectrum extending from FTLD-U to IBM and ALS. 
IBMPFD is now known to be part of this spectrum. Immunostaining for TDP-43 in the 
central nervous system of patients with VCP mutations revealed robust pathology 
consisting of nuclear and cytoplasmic inclusions, and dystrophic neurites that overlaps 
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with immunostaining for ubiquitin (Fig 1.5). Furthermore, accumulations of TDP-43 co-
localized with the ubiquitin pathology in IBMPFD including both the intranuclear 
inclusions and dystrophic neurites. In neurons and glia without ubiquitin pathology, 
both in unaffected and affected brain regions, physiologic TDP-43 was robustly detected 
in the nuclei of neurons and glia. In contrast, there was a dramatic reduction in the 
labeling intensity of nuclear TDP-43 in affected cortex (Fig 1.5B). A biochemical analysis 
of IBMPFD brain tissue revealed insoluble phosphorylated TDP-43 only in extracts from 
affected brain regions similar to sporadic FTLD-U (Neumann et al. 2007). 
 The presence of a pathological signature of TDP-43 in IBMPFD is not limited to 
the FLTD-U component. TDP-43 is a highly conserved protein with ubiquitous expression 
and was recently identified in normal muscle nuclei and also in nonnuclear sarcoplasm 
(Weihl et al. 2008). Immunoreactivity to sarcoplasmic TDP-43 and TDP-43-positive 
inclusions are now considered to be the most sensitive and specific diagnostic 
immunohistochemistry marker for sporadic and familial IBM (Weihl et al. 2008; Kusters 
et al. 2009; Olive et al. 2009). This suggests a common element in the pathogenesis of 
myopathies so researchers examined the IBM myofibers of IBMPFD patients (Salajegheh 
et al. 2009). They found an increased presence of TDP-43 sarcoplasmic 
immunoreactivity compared to normal muscle. Furthermore, the abnormal 
accumulation of TDP-43 in the sarcoplasm is accompanied by its nuclear depletion 
suggesting its redistribution from the myonucleus to the sarcoplasm is similar to the 
nuclear to cytoplasmic redistribution seen in affected cortical regions. Biochemical 
analysis of the TDP-43 from IBMPFD  patient muscle has not been able to conclusively 
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identify the hyperphosphorylated form seem in FTLD-U brain, possibly due to the 
contaminating effect of the immunoglobulin molecules commonly found in 
inflammatory IBM samples. Moreover, it has yet to be determined whether TDP-43 
metabolism is altered in affected muscle in IBMPFD similar to that observed in the brain. 
Additional work is necessary to define the importance of TDP-43 and whether its altered 
distribution, metabolism or function plays a meaningful role in the pathogenesis of 
IBMPFD. 
 
Many mechanisms of how VCP mutations cause disease are being researched 
 The mechanism whereby mutations in VCP lead to the pathogenesis of IBMPFD 
and the selective vulnerability of brain, muscle and bone remains unknown but many 
avenues of research are underway to answer the experimental questions raised by work 
to date: How do mutations affect VCP structure? Do mutations, particularly in the N 
domain of VCP, affect binding to VCP’s adaptor complexes? Do mutations affect known 
functions of VCP such as ERAD or other ubiquitin-dependent proteasomal pathways? Do 
mutations affect alternative degradative pathways such as autophagy? What role does 
TDP-43 play in the pathogenesis of IBMPFD? 
 The autosomal dominance of IBMPFD penetrance indicates a dominant 
mechanism – either a toxic gain of function or dominant negative activity. The dominant 
negative theory gains interest when it is considered that VCP functions as a hexameric 
complex and mutant forms of VCP retain the ability to form hexamers, even the A232E 
mutant form  in D1 of VCP, the domain responsible for hexamerization (Fig 1.2) (Weihl 
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et al. 2006; Halawani et al. 2009). However, it is a consistent finding that the ATPase 
activity of multiple VCP mutants is significantly increased (Halawani et al. 2009). This 
concept is antithetical to the dominant negative theory but strengthens the hypothesis 
that mutations in VCP result in the amplification of a native function. Recent structural 
studies do suggest that conformational defects could arise as a result of mutations in 
VCP and this could disrupt the interaction of the adaptor complexes and VCP’s N 
domain, where the majority of mutations reside (Fig 1.2A). Though not comprehensively 
studied, some differences have been observed in the binding of wild type versus mutant 
VCP with the adaptors Npl4, p47, ataxin-3 and Ube4b (Hubbers et al. 2007; Fernandez-
Saiz and Buchberger 2010) (Chapter 3). However, these studies report conflicting results 
and require further understanding. 
 Despite contradictory results in establishing whether mutations in VCP result in 
altered binding to the Ufd1-Npl4 adaptor complex, the presence of ubiquitinated 
inclusions in the affected tissue of IBMPFD patients, and VCP’s known role in UPS 
function, suggest that these mutations may somehow disrupt normal protein 
degradation (Schroder et al. 2005; Forman et al. 2006; Pirici et al. 2006). To that end, 
impairment of ERAD, one of the best characterized roles of VCP, has been implicated in 
IBMPFD pathogenesis. Specifically, the expression of mutant VCP in a myoblastic cell line 
was associated with increased immunodetection of ubiquitin-conjugated proteins 
(Weihl et al. 2006). In addition, in a subset of transfected cells, IBMPFD mutations were 
associated with the formation of aggregates that contain VCP, ubiquitin, ER resident 
proteins and elevated levels of exogenously expressed mutant CFTR, a protein degraded 
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by ERAD. This result is difficult to interpret however since the CFTR 508 mutant is also 
degraded by autophagy (Iwata et al. 2005; Fu and Sztul 2009). In addition, other studies 
have not confirmed the cell culture findings described above. In one study,  a 
catalytically-dead VCP and VCP harboring disease-associated mutations were expressed 
in a reporter cell line expressing CD3 -YFP (Tresse et al. 2010). This construct provides a 
fluorescent signal that is highly sensitive to impairment of the ERAD pathway of 
proteasomal degradation (Menendez-Benito et al. 2005). Catalytically-dead VCP 
impaired the ERAD pathway in vitro. No impairment was seen in cells expressing 
disease-associated VCP mutants. This study also demonstrates that dominant negative 
VCP can have a different effect on cellular function than IBMPFD-associated mutations. 
Perhaps if ERAD is not impaired then another ubiquitin-dependent proteasomal 
pathway is affected by VCP mutations? A complex of VCP, UFD2/Ube4b and CHN-1 was 
recently implicated in myosin assembly and myofibril organization by regulating the 
expression of Unc45b, a molecular chaperone implicated in myosin assembly (Janiesch 
et al. 2007). The expression of IBMPFD-associated VCP mutations in skeletal muscle cells 
reduced Unc45b degradation that correlated with severe myofibril disorganization in 
myotubules. However, another study using stable reporter cells expressing the UFD 
substrate UbG76V-YFP and transiently expressing mutant VCP (dominant negative and 
disease-associated) found that only dominant negative VCP impaired the UFD pathway 
(Tresse et al. 2010).  
 This work highlights that if there is impairment in the degradation of substrates 
within IBMPFD, then it may not be the proteasomal pathways that are affected by VCP 
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mutations. What alternative degradation pathways could be involved? Muscle biopsies 
from affected muscle in IBMPFD patients as well as muscle from two transgenic mouse 
models of IBMPFD display ubiquitinated inclusions and the presence of rimmed vacuoles 
(Weihl et al. 2007; Kimonis et al. 2008; Custer et al. 2010). A disease model of IBM in 
rats has previously tied the muscle atrophy and rimmed vacuole formation to 
accumulated autophagosomes (Suzuki et al. 2002). Indeed, myoblasts derived from 
IBMPFD patients demonstrate an accumulation of LAMP-1/2-positive vacuoles (Tresse 
et al. 2010). In addition, ultrastructural analysis of rimmed vacuoles from IBM patient 
muscle reveals them to be autophagic vacuoles containing filamentous material 
(Hubbers et al. 2007).  
 Autophagy is a catabolic process in which sequestered cytosolic components are 
delivered to a specialized compartment for degradation by lysosomal hydrolases. 
Substrates are initially sequestered within double-membraned, immature autophagic 
vesicles that then fuse with lysosomes to degrade the contents (De Duve and Wattiaux 
1966). The muscle pathology seen in IBMPFD models and patient tissue suggests a 
possible link between VCP mutations and compromised autophagy. Indeed, there is 
significant clinical overlap of IBMPFD and disease caused by mutations in other genes 
related to autophagy e.g. SQSTM1/p62. SQSTM1/p62 is responsible for the delivery of 
ubiquitinated proteins to the autophagy system (Moscat and Diaz-Meco 2009). 
Mutations in this gene cause a form of Paget’s disease of bone indistinguishable from 
the form caused by mutations in VCP (Hocking et al. 2002). This implies that VCP and 
p62 share a common biological pathway. VCP’s full role in autophagy has yet to be 
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determined but it has been found to be essential to autophagosome maturation under 
basal conditions and in cell challenged by proteasome inhibition, but not in cells 
challenged by starvation. This suggests that VCP might be selectively required for 
autophagic degradation of ubiquitinated substrates. Expression of mutant VCP in cells 
results in significant accumulation of immature autophagic vesicles (Tresse et al. 2010). 
This mirrors the accumulation of immature autophagosome-associated proteins such as 
Map1-LC3, LC3II and p62 in IBMPFD muscle (Ju et al. 2009; Tresse et al. 2010). 
Interestingly, TDP-43 accumulates in the cytosol of cells upon autophagic inhibition, 
similar to that seen after IBMPFD mutant expression (Caccamo et al. 2009; Gitcho et al. 
2009; Ju et al. 2009; Custer et al. 2010). Therefore, the accumulation of TDP-43 
observed in IBMPFD may be a consequence of autophagy deficiency. 
It has been discussed so far in this review that TDP-43 
redistribution/accumulation is recognized as a pathological feature in many diseases 
including IBMPFD although the significance of this is unclear. TDP-43, under 
physiological conditions, undergoes nucleocytoplasmic shuttling (Ayala et al. 2008). 
After neuronal injury, TDP-43 redistributes to the cytoplasm where it associates with 
stress granules (Colombrita et al. 2009; Moisse et al. 2009). Though a prominent feature 
of disease, it is not known whether disease-associated cytoplasmic accumulation of 
TDP-43 is a mediator of pathology or a physiological response to it. The recent 
identification of disease-associated mutations in TDP-43 strongly implicates this protein 
in disease pathogenesis (Gitcho et al. 2008; Kabashi et al. 2008; Rutherford et al. 2008; 
Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki et al. 2008). Indeed a 
20 
transgenic rat model of neurodegeneration caused by TDP-43 harboring the familial 
mutation M337V recapitulates features of TDP-43 proteinopathies including the 
formation of TDP-43 inclusions, cytoplasmic localization of TDP-43 and fragmentation of 
TDP-43 protein (Zhou et al. 2010). The question of how TDP-43 accumulation occurs in 
IBMPFD and how it could contribute to pathology remains unanswered.    
 
Summary 
 Clearly, elucidating the mechanism of VCP-mediated IBMPFD requires further 
investigation. While disruption of ERAD and/or UPS function is an attractive hypothesis, 
mutations in VCP may affect other cellular activities regulated by VCP such as Golgi, ER 
or myofibril assembly. Alternatively, mutations in VCP may lead to a novel, toxic gain of 
function that is not otherwise predicted based on its known functions. TDP-43 appears 
to be a pathologic substrate linking a variety of distinct patterns of FTLD-U pathology 
caused by different genetic alterations. Elucidating TDP-43’s role in the pathogenesis of 
IBMPFD could provide insight in to diseases. Finally, IBMPFD is a multisystem disease 
affecting the brain, muscle and bone. Understanding the selective vulnerability of 
penetrance of these phenotypes will ultimately lead to a better understanding of the 
IBMPFD as well as the sporadic counterparts FTD, IBM and Paget’s disease of bone. 
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Table 1.1 Clustal 2.0.10 multiple sequence alignment for VCP/p97/TER94/CDC48 with 
disease-associated residues highlighted. 
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ABSTRACT 
Inclusion body myopathy associated with Paget’s disease of bone and 
frontotemporal dementia (IBMPFD) is a dominantly inherited degenerative disorder 
caused by mutations in the valosin-containing protein (VCP) gene. VCP (p97 in mouse, 
TER94 in D. melanogaster, and CDC48 in S. cerevisiae) is a highly conserved AAA+-ATPase 
that regulates a wide array of cellular processes. The mechanism of IBMPFD 
pathogenesis is unknown. To elucidate the pathogenic mechanism, we developed and 
characterized a Drosophila model of IBMPFD (mutant VCP–related degeneration). Based 
on genetic screening of this model we identified three RNA-binding proteins that 
dominantly suppressed degeneration; one of these was TBPH, the Drosophila homolog 
of TAR DNA-binding protein (TDP-43). Here we demonstrate that VCP and TDP-43 
interact genetically and that disease-causing mutations in VCP lead to redistribution of 
TDP-43 to the cytoplasm in vitro and in vivo, replicating the major pathology observed in 
IBMPFD and other TDP-43 proteinopathies. We also demonstrate that TDP-43 
redistribution from the nucleus to the cytoplasm is sufficient to induce cytotoxicity. 
Furthermore, we determined that a pathogenic mutation in TDP-43 promotes 
redistribution to the cytoplasm and enhances the genetic interaction with VCP. Taken 
together, our results show that degeneration associated with VCP mutations is 
mediated in part by toxic gain-of-function of TDP-43 in the cytoplasm. We suggest that 
these findings are likely relevant to the pathogenic mechanism of a broad array of TDP-
43 proteinopathies, including frontotemporal lobar degeneration and amyotrophic 
lateral sclerosis. 
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INTRODUCTION 
Inclusion body myopathy associated with Paget’s disease of bone and 
frontotemporal dementia (IBMPFD; MIM167320) is a rare, complex and ultimately lethal 
autosomal dominant disorder. Affected individuals exhibit variable penetrance of 
progressive degeneration of muscle, bone and brain caused by mutations in the gene 
encoding valosin-containing protein (VCP) (Watts et al. 2004) (Kimonis et al. 2008). The 
molecular chaperone VCP (also known as p97, TER94, and CDC48) is a member of the 
AAA+ family of proteins (ATPases associated with multiple cellular activities) that 
segregates ubiquitinated substrates from multimeric protein complexes or structures 
(Ye 2006). VCP activity is essential for multiple cellular processes, including ubiquitin-
dependent protein degradation, nuclear envelope construction, Golgi and endoplasmic 
reticulum assembly, and autophagosome maturation (Halawani and Latterich 2006; Ju 
et al. 2009; Tresse et al. 2010). The molecular basis of degeneration resulting from VCP 
mutations is unknown, although ubiquitin-positive pathology is prominent in affected 
tissues (Guinto et al. 2007; Weihl et al. 2008). TAR DNA-binding protein 43 (TDP-43) has 
been identified as a major component of the ubiquitin pathology (Neumann et al. 2007; 
Salajegheh et al. 2009).   
TDP-43 is a predominantly nuclear hnRNP that undergoes nucleocytoplasmic 
shuttling and associates with translation machinery in the cytoplasm (Ayala et al. 2008; 
Wang et al. 2008; Freibaum et al. 2009). TDP-43 is redistributed to the cytoplasm after 
neuronal injury where it associates with stress granules (Colombrita et al. 2009; Moisse 
et al. 2009). TDP-43 redistribution to the cytoplasm is recognized as a pathological 
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feature of several sporadic and inherited human diseases including IBMPFD, 
frontotemporal dementia and amyotrophic lateral sclerosis, although the significance of 
this is unclear (Neumann et al. 2007; Geser et al. 2009; Salajegheh et al. 2009). TDP-43 
redistribution has also been observed in vitro in cells expressing mutant VCP, although 
the role of TDP-43 in mediating disease has not been explored (Gitcho et al. 2009). The 
recent identification of disease-associated mutations in TDP-43 strongly implicate this 
protein in disease pathogenesis (Gitcho et al. 2008; Kabashi et al. 2008; Rutherford et al. 
2008; Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki et al. 2008), although it 
is not known whether disease-associated cytoplasmic accumulation of TDP-43 is a 
mediator of pathology or a physiological response to it. 
Here we present the first Drosophila melanogaster model of IBMPFD. Through 
genetic screening we identified three RNA-binding proteins that suppress degeneration. 
One of these was TBPH, the fly orthologue of TDP-43. We show in vitro that expression 
of disease-causing VCP mutants leads to cytotoxicity and coincidental redistribution of 
TDP-43. To determine the significance of TDP-43 redistribution, we generated 
transgenic flies expressing wild type (WT) and mutant forms of TDP-43.  We 
demonstrate that VCP and TDP-43 interact genetically, that disease-causing mutations 
in VCP lead to redistribution of TDP-43 to the cytoplasm in vivo, and that redistribution 
of TDP-43 is sufficient to induce degeneration in vivo. Thus, our study provides the first 
evidence that toxic gain-of-function of TDP-43 in the cytoplasm plays a primary role in 
mediating the pathogenesis initiated by mutations in VCP. 
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MATERIALS AND METHODS 
Plasmids 
To generate pUAST-dVCP constructs, dVCP cDNA in the pBluescript SK- (pBS 
sequence variants were generated using Stratagene’s QuikChange SDM Kit (Agilent 
Technologies, Cedar Creek, CA), changing R to H at amino acid (aa) 152 (R152H), A to E 
at aa 229 (A229E) and subsequently subcloned into pUAST. To generate DsRed VCP, VCP 
cDNA was obtained from Origene and sequence variants R95G, R155H, R155C, R191Q 
and A232E were generated using Stratagene’s QuikChange SDM kit. Wild type and 
mutant VCP were then subcloned into the BglII/BamH1 cloning site of pDsRed 
Monomer-C1 vector (Clontech). TBPH cDNA was obtained from Origene and subcloned 
into the EcoRI/XhoI site of pUAST. WT, NLS- and NES-mutant TDP-43 cDNAs were 
amplified from the previously described mammalian expression constructs (Winton et 
al. 2008). Using the Stratagene’s QuikChange SDM kit, TDP-43 M337V (M to V at aa337) 
was generated from WT TDP-43. All TDP-43 constructs were subcloned into the 
NotI/XhoI cloning site of pUAST.  
 
Fly culture 
All Drosophila stocks were maintained on standard media in 25oC incubators. 
Double-strand RNAi lines targeting TBPH (ID38377), xl6 (ID31202, ID31203) and Hrb27C 
(ID16040, 16041) were obtained from the Vienna Drosophila RNAi Center. Flies 
transgenic for UAS-dVCP (WT or mutant), UAS-TBPH and UAS-TDP-43 (WT or mutant) 
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were generated by injecting the constructs described above into embryos of w1118 
using standard techniques. 
 
Dominant modifier screen 
Deficiency (Df) lines for all four chromosomes obtained from the Bloomington 
stock center were used to identify dominant modifiers of mutant dVCP in a genetic 
screen. For the primary screen, balanced virgin female dVCP R152H (recombined with 
Gmr GAL4) flies were crossed with Df/Balancer males from 270 deficiency lines and 
progeny were examined for changes in eye phenotype (including color, ommatidia 
structure and bristle formation). At least ten progeny were examined and scored on a 
twenty-point scale. Eyes were examined for the presence of: supernumerary inter-
ommatidial bristles (IOBs), IOBs with abnormal orientation, necrotic patches, a decrease 
in size, retinal collapse, fusion of ommatidia, disorganization of ommatidial array and 
loss of pigmentation. Points were added if: there was complete loss of IOBs (+1), more 
than 3 small or 1 large necrotic patch (+1), retinal collapse extended to the midline of 
the eye (+1) or beyond (+2), loss of ommatidial structure in less than 50% (+1) or more 
than 50% (+2) of the eye, and if pigmentation loss resulted in change of eye color from 
red to orange (+1) or pale orange/white  (+2). Gmr, GAL4, UAS dVCP R152H / Balancer 
served as an internal control. In a secondary screen to filter nonspecific modifiers of cell 
death, deficiencies defined as hits (either enhancing or suppressing the dVCP mutant 
phenotype) were then crossed with flies expressing the pro-apoptotic gene Reaper 
(recombined with Gmr GAL4). Any hits that similarly affected dVCP R152H and Reaper in 
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the secondary screen were excluded from further study due to the possibility of non-
specific anti-apoptotic effects. As regions of interest were identified from the primary 
and secondary screens, additional Df lines were obtained that overlapped with 
interacting deficiencies to verify and refine the position of potential modifiers.  For the 
final step of gene identification, individual RNAi lines corresponding to the genes within 
the candidate intervals were obtained from the Vienna Drosophila RNAi Center. Gmr 
GAL4, UAS dVCP R152H females were crossed with males from the RNAi lines and the 
progeny eyes were evaluated for changes. A modifier was defined as an RNAi line that 
replicated the enhancement or suppression of the corresponding deficiency. 
 
Cell culture and transfection 
HEK293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% L-
glutamate. HEK293T cells were transfected with Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol. Primary cortical neurons were cultured from 
postnatal day zero C57Bl/6J pups. Briefly, pups were decapitated into Hanks medium 
without Ca2+ and Mg2+, and cortices were dissected in Neurobasal-A medium 
supplemented with 10 mM HEPES. After dissection, cortices were trypsinized for 25 
minutes at 37oC and dissociated. Neurons were plated in Neurobasal-A with B27 
supplement at a density of 2.5 x 105 cells per well in 4-well chamber CC2 slides (Nalge-
Nunc). After 4 days in vitro (DIV), cells were transfected with 1ug plasmid DNA using 
Lipofectamine 2000 (Invitrogen) as suggested by the manufacturer. 
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Immunoblots 
To examine soluble and insoluble fractions of TDP-43 in cells, HEK293T cells were 
harvested at the indicated times and RIPA-soluble and insoluble fractions were prepared 
as previously described (Winton et al. 2008). To examine proteins expressed in flies, 3 
fly heads (or thoraces) of the appropriate genotype were lysed in 20 μL of RIPA. For 
immunoblots (IB), 20 μg of cell lysates or lysate from 3 fly head equivalents were 
resolved on 10% SDS-PAGE and transferred to a nitrocellulose membrane (BioRad), and 
IB was performed as described (Pandey et al. 2007). Mouse monoclonal anti-VCP 
antibody (Affinity BioReagent) was used at 1:10000; rabbit polyclonal anti-TDP-43 
antibody raised against recombinant TDP-43 (Protein Tech Group) at 1:1000; mouse 
monoclonal anti-tubulin (Sigma) at 1:10000; and rabbit polyclonal anti-actin (Santa Cruz) 
at 1:3000. Primary antibodies were detected with horseradish peroxidase–conjugated 
anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch) and proteins were visualized 
using Immobilon Western Chemiluminescent AP Substrate (Millipore). 
 
Real-time quantitative PCR 
Total RNA was isolated from 10 animals of the appropriate genotype with TRIzol 
reagent (Invitrogen) and cDNA was generated using the iScript cDNA Synthesis kit 
(BioRad) following the manufacturer’s protocol. The concentration of each primer probe 
set was individually optimized. Quantitative real-time PCR reactions were carried out in 
a total reaction volume of 25 l of iQ Supermix (BioRad) using BioRad iCycler iQ5. 
Transcript levels were normalized to dGAPDH2. The primer/probe set for genes 
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purchased from Applied Biosystems were as follows: Hrb27C-- Dm01803323_g1, xl6--
Dm01803314_m1, TBPH--Dm01820181_g1 and GAPDH2 ctl.--Dm01843776_S1. 
 
Cytotoxicity assays 
To assess toxicity in HEK293T cells, cells were harvested at the indicated times 
with versene, rinsed with PBS, and resuspended in PBS + 1% FBS. TOPRO-3 (Molecular 
Probes) in 1 mM DMSO was diluted 1:50000 in PBS and 50 μL was added to 450μL of the 
cell suspension. After incubation for 1-2 min, cells were analyzed by FACS. Transfected 
cells were identified by DsRed fluorescence and dead cells were identified by TOPRO-3 
fluorescence. Cell viability was calculated and expressed as previously described (Taylor 
et al. 2003). To assess toxicity in primary cortical neurons, we transfected these cells on 
day 4 in vitro with DsRed-conjugated WT or mutant VCP. Twenty-four or 48 hours post-
transfection, neurons were immunostained for MAP2 and stained with DAPI to visualize 
nuclear morphology as described above. A blinded investigator scored VCP-expressing 
neurons for the presence or absence of toxicity. Only neurons with both condensed 
nuclei and loss of MAP2 staining were scored positive for cytotoxicity. More than100 
neurons from at least 3 trials were analyzed and results were compared by using the 
Student t-test with a significance threshold of p<0.05). 
 
Transcription assays 
HEK293T cells were transfected with firefly luciferase reporter constructs (pLTR, 
pSP10 or pSP10D) combined with 100ng pRL-CMV and 0.5ug VCP WT, VCP R155H, VCP 
31 
A232E or empty vector control (pcDNA 3.1) by using Fugene (Roche) according to the 
manufacturer’s protocol. Forty-eight hours after transfection, cell lysates were analyzed 
using the Stop and Glo dual reporter system (Promega) in a 96-well format with a 
Vector3 luminometer, as directed by the Promega protocol. Firefly luciferase activity 
was then normalized to the Renilla luciferase activity to control for transfection 
efficiency. Data was then normalized to activity in cells transfected with empty vector 
control, which was given a value of 1. 
 
Histology 
For immunofluorescence analysis in cell culture, HEK293T and HeLa cells were 
washed twice with PBS, fixed with 4% PFA for 10 minutes, washed twice with PBS, then 
permeabilized with 0.2% Triton X-100 in PBS for 10 minutes and blocked with 0.2% 
Triton/5% goat serum in PBS for 30 minutes. Cells were incubated with primary antibody 
(rabbit polyclonal anti-TDP-43 antibody at 1:200 and mouse monoclonal anti-MAP2 at 
1:500, diluted in PBS containing 0.2% Triton/5% goat serum) for 1.5 hour and washed 
twice with PBS (15 minutes each). After the final wash, the cells were incubated with 
secondary antibody (diluted in PBS containing 0.2% Triton/5% goat serum) for 1 hour, 
washed three times with PBS (5 minutes each), and mounted with Vectashield + DAPI 
(Vector Laboratories Inc). Digital imaging was performed with a Leica DMIRE2 
fluorescent microscope using IP-LAB or Slidebook 5.1 software. To quantify 
fluorescence, regions of interest were drawn around the nuclei or cytoplasm of 
transfected (DsRed-positive) cells or untransfected neighboring cells and the intensity of 
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FITC fluorescence emission from >100 cells was measured in at least three experiments. 
For immunofluorescence analysis in Drosophila salivary glands, at least 5 third instar 
wandering larvae expressing dVCP (WT or mutant) and TDP-43 (WT or mutant) under 
control of the driver fkh-GAL4 were collected. Salivary glands from these larvae were 
dissected in PBS and fixed in 4% PFA and heptane at room temperature. After 20 
minutes, the PFA was removed and 100% methanol added. After vigorous shaking for 1 
minute the heptane was removed and the samples washed in methanol 3 times. After 3 
washes in PBST (PBS/0.1% Tween-20) and 3 washes in PBSBT (PBS/0.1% Tween-20/1% 
BSA) the samples were blocked for 2 hours in PBSBT at room temperature. Samples 
were incubated with primary antibody (rabbit polyclonal anti-TDP-43 antibody at 1:300, 
diluted in PBSBT) overnight and washed 4 times with PBSBT (30 minutes each). After the 
final wash, the cells were incubated with secondary antibody (diluted in PBSBT) for 2 
hours, washed three times with PBSBT (10 minutes each), and mounted with ProLong 
Gold antifade reagent with DAPI (Invitrogen). Digital imaging was performed with a 
Leica DMIRE2 fluorescent microscope using Slidebook software. All cells from the glands 
were evaluated for the absence of nuclear TDP-43 staining. Using Slidebook software, 
DAPI was pseudo-colored in red. 
For immunohistochemistry of fly eyes, heads of the appropriate genotype were 
collected and fixed in 4% buffered paraformaldehyde in PBS for 2 hours at room 
temperature. Samples were serially dehydrated in ethanol (1 h each in 50%, 70%, 80%, 
90%, 95%, and twice in 100%). Samples were then either: (1) embedded in JB-4 
according to the manufacturer’s protocol (JB-4 Plus Embedding Kit, Polysciences, Inc.) 
33 
and sectioned at 1 micron for staining with Richardson’s or toluidine blue stains, or (2) 
embedded into paraffin, sectioned at 5 microns, and placed on glass slides. 
Immunohistochemistry was performed using (ProteinTech) rabbit anti-TDP43 at 1:200, 
Vector Rabbit HRP ImmPress detection, and Vector AEC substrate. 
 
RESULTS 
Exogenous expression of disease-related VCP mutants causes toxicity in a novel 
Drosophila melanogaster model 
To develop an in vivo model of VCP-mediated degeneration, we used Drosophila 
melanogaster, in which the gene TER94 encodes the highly conserved orthologue of 
VCP. The Drosophila VCP orthologue, hereafter referred to as dVCP, is 92% similar and 
83% identical to human VCP at the amino acid level. Conservation is even higher (95% 
similar, 84% identical) across the 250–amino acid N-terminus, which hosts most known 
disease-causing mutations, and all amino acid residues altered in disease are perfectly 
conserved. We introduced R152H and A229E mutations into dVCP to create homologs of 
the R155H and A232E mutations, which cause the most common and most severe forms 
of IBMPFD, respectively, and generated transgenic flies. When these mutants were 
expressed in the fly eye, brain or muscle using the UAS/GAL4 system (Brand and 
Perrimon 1993) we observed mutation-dependent degenerative phenotypes despite 
equivalent levels of dVCP expression (Fig 2.1, S2.1). In the eye, expression of WT dVCP 
caused a very modest phenotypic change, whereas matched expression of the R152H 
and A229E mutants caused severe external rough eye phenotypes with necrotic patches 
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and histologically evident marked vacuolar degeneration. The more severe phenotype 
seen in flies expressing the A229E mutant is consistent with the more severe disease in 
patients with the A232E mutation. 
When expressed broadly in the central nervous system, mutant dVCP reduced 
viability by diminishing eclosion rates (Fig. S2.1A), and surviving male flies had a 
significantly reduced lifespan indicative of neurodegeneration (Fig. S2.1B-C). Flies 
expressing dVCP in the central nervous system also display a mutation-dependent 
decrease in eclosion rates (Fig. S2.1D). When the indirect flight muscles of these flies 
were examined by electron microscopy, we noted marked abnormalities associated with 
the mutant dVCP-expressing flies, including myofibril disruption, both in longitudinal 
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and cross-sections, particularly at the M line. Mitochondrial pleioconia and megaconia 
were commonly found associated with mutant dVCP flies (Fig. S2.1E-F). Thus, this fly 
model recapitulates the degeneration associated with disease-causing mutations in VCP 
in tissue known to be affected (brain and muscle) and in a non-essential tissue (eye), 
which allows screening to identify modifying genes. 
 
A dominant modifier screen identifies RNA-binding proteins, including TBPH, as 
modifiers of mutant-dVCP toxicity 
VCP participates in a range of cellular activities and thus in diverse biological 
pathways. The specific pathways underlying pathogenesis of IBMPFD, however, are 
unknown. As an unbiased approach to identify molecules and pathways involved in 
mutant VCP–mediated degeneration, we performed a dominant-modifier screen, using 
the moderate dVCP mutant phenotype of dVCP R152H to maximize the likelihood of 
visualizing enhancement or suppression of the mutant dVCP phenotype. To carry out the 
screen, we obtained a deficiency (Df) collection representing all four chromosomes from 
the Bloomington Drosophila Stock Center in order to scan the maximum proportion of 
genome (~80%) with the smallest number of lines. From the primary screen, seventy-
four deficiencies were identified as dominant modifiers (enhancers or suppressors) of 
the dVCP R152H eye phenotype. After the secondary screen, validation studies and 
individual gene interrogation by double-strand RNAi lines, we identified three related 
genes: TBPH (CG10327), xl6 (CG10203) and Hrb27C (CG10377) that dominantly suppress 
the degenerative phenotype (Fig 2.2A-B). RNAi-mediated knockdown of these genes in 
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the eye did not result in a phenotypic change independent of mutant dVCP expression 
(Fig. S2.2A-D). However, in flies expressing dVCP R152H, knockdown of these genes 
suppressed mutation-dependent degeneration (Fig 2.2B). Suppression of degeneration 
in VCP-mutant flies was corroborated by seeing a significant reduction in the blinded 
phenotypic severity score (Fig 2.2C) and by using additional RNAi lines and classical 
alleles (Fig S2.2E-F). We also generated transgenic lines over-expressing TBPH, which 
resulted in a degenerative phenotype evident externally and histologically when 
targeted to the eye. When exogenous TBPH was co-expressed  with dVCP R152H, 
degeneration associated with mutant VCP was enhanced, confirming the genetic 
interaction (Fig 2.2D). Hrb27C, xl6 and TBPH correspond to the human genes DAZAP1, 
9G8 and TDP-43, respectively.  These are all RNA recognition motif (RRM)-containing 
RNA-binding proteins that shuttle between the nucleus and cytoplasm (Huang and Steitz 
2001; Lin and Yen 2006; Ayala et al. 2008). Furthermore, all three have been shown to 
regulate multiple aspects of RNA metabolism, including transcription, export, splicing 
and translation (Elvira et al. 2006; Swartz et al. 2007; Yang et al. 2009). We focused on 
TDP-43 for further assessment, because cytoplasmic deposition of this protein is a 
prominent feature of IBMPFD and other degenerative diseases (Geser et al. 2009).  
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Disease-related mutations in VCP cause cytotoxicity and lead to TDP-43 redistribution 
In the brain, TDP-43 is found predominantly in the nuclei of neurons and some glial cells 
(Fig. 2.3A), although dynamic studies in vitro have shown TDP-43 to shuttle between the 
nucleus and cytoplasm (Ayala et al. 2008). In IBMPFD, affected brain regions show gross 
abnormalities in TDP-43 localization, including clearance of TDP-43 from many nuclei 
and accumulation in the cytoplasm; some neurons show dense nuclear inclusions of 
TDP-43 (Fig. 2.3B). To examine the subcellular localization of TDP-43 in vitro, we first 
investigated whether VCP mutation-dependent toxicity could be recapitulated in 
primary mouse cortical neurons transfected with FLAG-conjugated WT VCP or mutant 
VCP (R155H and A232E). At 24 or 48 hours post-transfection, a blinded examiner scored 
VCP-positive neurons for changes in MAP2 staining and nuclear morphology (changes in 
DAPI staining) to assess cytotoxicity (Fig. 2.3C). Quantitative analysis of the data 
revealed significant mutation-dependent toxicity in primary neurons 48 hours post-
transfection (Fig. 2.3D). This time-dependent cytotoxicity caused by mutant VCP was 
also demonstrated by fluorescence-activated cell sorting for living vs. dead HEK293T 
cells. Exogenous expression of mutant but not WT VCP caused cell death despite 
equivalent levels of VCP expression (Fig. S2.3A-B). 
To examine TDP-43 subcellular localization, we fixed and immunostained 
primary mouse cortical neurons twenty-four hours post-transfection, before occurrence 
of the changes in MAP2 staining or nuclear morphology. In neurons expressing FLAG 
vector alone or FLAG-conjugated WT VCP, TDP-43 was consistently nuclear. By contrast, 
in cells transfected with mutant VCP, we observed significant clearance of endogenous 
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 TDP-43 from nuclei and accumulation in the cytoplasm (Fig. 2.3E-G). Redistribution of 
endogenous TDP-43 to the cytoplasm was also observed in HEK293T cells expressing 
mutant but not wild type VCP (Fig. S2.3C-D). Exogenous expression of TDP-43 increased 
the amount of cytoplasmic redistribution (Fig. S2.3E-F). The nuclear depletion of TDP-43 
in primary neurons and HEK293T cells was corroborated by an associated loss of TDP-
43’s known nuclear function as a transcriptional repressor of testis-specific SP-10 gene 
(Acharya et al. 2006). TDP-43 has been shown to interact with the SP-10 insulator, which 
prevents luciferase expression by repressing the interaction between the CMV enhancer 
and SP-10 core promoter in the pSP-10 construct (Fig. 2.3H). Mutation of the two TDP-
43 binding sites (ACACAC to GGGTTG) compromises the enhancer-blocking ability of the 
SP-10 insulator, allowing luciferase expression (Fig. 2.3H). HEK293T cells were 
transfected with pSP10 or pSP10-mutant luciferase reporter constructs and luciferase 
expression was quantified forty-eight hours post-transfection as an indicator of TDP-43 
nuclear function. When TDP-43 binding to SP10 was disrupted by use of the pSP10-
mutant or by siRNA knockdown of TDP-43, thenormal repression of luciferase 
expression was attenuated. When mutant VCP, but not WT VCP, was co-transfected 
with pSP10, the repression was released, allowing a significant increase in luciferase 
expression. Cells co-transfected with VCP constructs and mutant pSP10 did not show 
greater luciferase activity than cells transfected with pSP10-mutant alone. Similar 
results were found using the HIV-1 luciferase reporter plasmid (pLTR) (Fig. S2.3G), a 
construct previously shown to rely on TDP-43 as a transcriptional repressor (Ou et al. 
1995). Thus, mutation-dependent VCP toxicity in primary neurons and HEK293T cells 
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was coincident with TDP-43 redistribution from the nucleus to the cytoplasm, as was 
also recently observed in immortalized SH-SY5Y and U20S cells (Gitcho et al. 2009; Ju et 
al. 2009). TDP-43 redistribution is also a conspicuous feature of numerous TDP-43 
proteinopathies. However, these observations do not tell us whether TDP-43 
redistribution represents an adaptive response to neuronal injury or, alternatively 
whether change in subcellular localization mediates disease. Furthermore, if TDP-43 
redistribution mediates disease, it leaves unclear whether the mechanism involves loss 
of nuclear function or toxic gain of cytoplasmic function. 
 
Mis-localization of TDP-43 to the cytoplasm causes degeneration 
To further investigate the potential role of TDP-43 mislocalization in mutant–
VCP-associated degeneration in vivo, we generated multiple transgenic flies expressing 
human WT or mutant TDP-43, using the UAS/GAL4 system. To target TDP-43 specifically 
to the nucleus or the cytoplasm, we used TDP-43 with previously characterized 
mutations that disrupt the nuclear export sequence (NES) or the nuclear localization 
sequence (NLS)(Winton et al. 2008). Five independent transgenic lines expressing WT 
TDP-43 in the fly eye showed a modest degenerative phenotype (Fig. 2.4, S2.4A-B and 
S2.6A). A normal eye phenotype was observed in 5 independent transgenic lines 
expressing NES-mutant TDP-43 (Fig 2.4, S2.4C-D and S2.6A). By contrast, expression of 
NLS-mutant TDP-43 in the fly eye in 6 independent lines resulted in a strong 
degenerative phenotype and high-molecular-weight smears of TDP-43 in immunoblots 
(Fig. S2.5A-B and S2.6). Immunostaining of NLS-mutant TDP-43 confirmed 
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predominantly cytoplasmic localization, while WT and NES-mutant TDP-43 remained 
predominantly nuclear (Fig. 2.4). To confirm that the degenerative phenotype was 
caused by cytoplasmic localization of TDP-43 rather than another effect of the NLS 
mutation, we also 
generated lines with 
truncated TDP-43 (80-
414). Deletion of the first 
seventy-nine amino acids, 
which disrupts the NLS, 
led to cytoplasmic 
localization of TDP-43 and 
a degenerative phenotype 
indistinguishable from 
that observed with NLS-mutant TDP-43 (Fig. S2.5C and data not shown). These findings 
indicate that accumulation of TDP-43 in the cytoplasm is sufficient to cause 
degeneration. Together with the observation that knockdown of TBPH in flies causes no 
phenotypic change alone but suppresses the mutant dVCP phenotype, these results 
indicate that a toxic gain of cytoplasmic TDP-43 function underlies pathogenesis. 
However, these observations do not preclude the possibility that a loss of TDP-43 
nuclear function contributes to toxicity. 
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An ALS-causing mutation expressed in vivo leads to toxicity associated with 
cytoplasmic redistribution of TDP-43 
Missense mutations in TDP-43 have recently been identified in association with 
dominantly inherited 
and sporadic ALS. To 
assess the effect of 
mutant TDP-43 in 
vivo, we generated 
transgenic lines 
expressing TDP-43 
with the ALS-causing 
mutation M337V 
(Sreedharan et al. 
2008). In 6 
independent lines 
evaluated, we 
observed 
degenerative 
phenotypes ranging 
from modest to 
severe (Fig 2.5A and S2.6A). The severity of the phenotype correlated with the amount 
of abnormal TDP-43 species, including a C-terminal 25-kDa fragment and high molecular 
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weight bands (Fig 2.5 and S2.6B). This is similar to the pathogenic biochemical signature 
seen in patient tissue with TDP-43 proteinopathy (Neumann et al. 2007). 
Immunohistochemistry for TDP-43 in these eyes showed a marked cytoplasmic 
distribution of TDP-43, consistent with a recent report that this mutation increases 
cytoplasmic TDP-43 inclusions in vitro (Nonaka et al. 2009).  
 
Mutation-dependent genetic interaction of dVCP and TDP-43 is associated with 
cytoplasmic redistribution of TDP-43 in vivo 
To assess the relationship between dVCP and TDP-43 in vivo, we performed an 
epistasis study by co-expressing dVCP (WT or mutant) with TDP-43 (WT or mutant) and 
analyzing changes to external eye phenotype by light microscopy (Fig 2.6A) and in 
subcellular localization of TDP-43 by immunohistochemistry (Fig 2.6B). Crosses with 
most of our NLS-mutant TDP-43 lines resulted in lethality; we therefore used line #5 that 
exhibits a very mild phenotype (all lines are shown in Fig. S2.5A). Due to the severe 
degradative loss of internal eye tissue in some genotypes, immunohistochemistry of 
TDP-43 in the eye (Fig. 2.6B) was corroborated with quantitative immunofluorescence 
analysis of TDP-43’s subcellular distribution in larval salivary glands (Fig. 2.6C-D). 
This epistasis study indicated no interaction between WT dVCP and WT or NES-
mutant TDP-43 (Fig. 2.6A, C). However the combination of WT dVCP with a weak NLS-
mutant resulted in mild enhancement of the pathologic phenotype. The combination of 
WT dVCP with a strong NLS-mutant TDP-43 resulted in lethality. Notably, the subcellular 
distribution of WT and mutant  
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TDP-43 was not altered by co-expression with WT dVCP (Fig. 2.6B-D). By contrast, the 
degenerative phenotype of mutant dVCP-R152H was strongly enhanced by co-
expression of WT TDP-43 (Fig. 2.6A, C), and this result was associated with significant 
clearance of WT TDP-43 from nuclei and accumulation in cytoplasm (Fig. 2.6B-D). 
Importantly, the dVCP-R152H phenotype was not enhanced by co-expression with NES-
mutant TDP-43 (Fig. 2.6A, C), and the subcellular distribution of NES-mutant TDP-43 
remained nuclear (Fig. 2.6B-D). Unsurprisingly, the dVCP-R152H phenotype was 
enhanced by NLS-mutant TDP-43 (Fig. 2.6A, C), and NLS-mutant TDP-43 was found 
predominantly in the cytoplasm (Fig. 2.6B-D). When the ALS-associated mutation TDP-
43 M337V was co-expressed with WT dVCP, the phenotype was enhanced, and lethality 
resulted when the M337V mutant was co-expressed with mutant dVCP (Fig. 2.6A, C). 
Thus, genetic interaction between dVCP and WT TDP-43 was dependent on a disease-
causing mutation in dVCP and was associated with redistribution of TDP-43 from the 
nucleus to the cytoplasm. TDP-43 restricted to the nucleus failed to interact with 
mutant VCP. The interaction of VCP with a known ALS-causing TDP-43 mutant further 
underscores the importance of cytoplasmic TDP-43 in VCP mutation-dependent 
degeneration. 
 
DISCUSSION 
We have developed and characterized a highly tractable Drosophila model of 
IBMPFD that exhibits VCP mutation-dependent degeneration (Fig.2.1 and S2.1). Using 
this model we identified multiple, related RNA-binding proteins that genetically 
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modified degeneration and one of these was TBPH, the Drosophila orthologue of TDP-
43. We further demonstrated that VCP and TDP-43 interacted genetically, that disease-
causing mutations in VCP led to redistribution of TDP-43 to the cytoplasm in vitro and in 
vivo, and that this redistribution was sufficient to cause degeneration in vivo. We also 
determined that a pathogenic mutation in TDP-43 enhanced the genetic interaction 
with VCP. Taken together, our results show that toxic gain-of-function of TDP-43 in the 
cytoplasm contributes to degeneration initiated by mutations in VCP. 
TDP-43 pathology is a prominent pathological feature in a broad array of 
sporadic and inherited human diseases including ALS, FTD-TDP, Perry Syndrome and 
IBMPFD (Neumann et al. 2007; Geser et al. 2009; Salajegheh et al. 2009). In these 
diseases, TDP-43 is found to be redistributed from the nucleus to the cytoplasm in 
affected neurons, although the significance of this has been unclear. In brain and muscle 
of IBMPFD patients, TDP-43 redistributes to the cytoplasm where it co-localizes with 
ubiquitin-immunopositivity, and is also present in lenticular nuclear inclusions (Guinto et 
al. 2007). Expression of mutant VCP in SH-SY5Y cells (Gitcho et al. 2009), U20S cells (Ju 
et al. 2009) and in primary neurons (Fig. 2.3) resulted in redistribution of TDP-43 to the 
cytoplasm, although no nuclear inclusions were observed. TDP-43 also redistributes to 
the cytoplasm in response to neuronal injury where it co-localizes with stress granules 
(Colombrita et al. 2009; Moisse et al. 2009). Therefore, it was unclear whether the 
redistribution of TDP-43 in the setting of mutant VCP-related disease was a mediator of 
pathogenesis or an indicator of cytotoxic stress caused by disease. The results presented 
here clarify this issue, indicating that TDP-43 is a mediator of toxicity initiated by 
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disease-causing mutations in VCP. This is illustrated by suppression of degeneration in 
the IBMPFD model when endogenous TBPH is depleted (Fig. 2.2B, C) and enhancement 
of degeneration when TBPH or TDP-43 is over-expressed (Fig. 2.2D and 2.6).  While our 
results indicate that accumulation of TDP-43 in the cytoplasm contributes to 
cytotoxicity, they do not exclude the possibility that depletion of nuclear TDP-43 also 
contributes to cytotoxicity. 
The mechanism by which mutations in VCP influence the subcellular distribution 
of TDP-43 is unknown, but we outline several possibilities here (Fig. 2.7). First, the 
nuclear depletion and cytoplasmic accumulation of TDP-43 might reflect a defect in the 
well-established role of VCP in ubiquitin-dependent segregation of substrates from 
multiprotein complexes. It is known that TDP-43 is present in the cytoplasm at low 
levels normally, where it is found in ribonucleoprotein complexes implicated in 
translation regulation (Freibaum et al.; Elvira et al. 2006; Wang et al. 2008; Moisse et al. 
2009). Perhaps VCP activity is necessary for removal of TDP-43 from ribonucleoprotein 
complexes to permit recycling and impairment of this activity by disease-causing 
mutations leads to progressive accumulation of TDP-43 in the cytoplasm. A second 
possibility is that VCP directly participates in nuclear import of TDP-43. VCP was 
previously shown to regulate the nuclear import of the TSAd protein (T cell-specific 
adaptor protein) in T cell signal transduction (Marti and King, 2005).  This aspect of VCP 
function may involve the adaptor Npl4 (nuclear protein localization-4), originally 
discovered in a yeast screen for mutants deficient in nuclear protein import (DeHoratius 
and Silver, 1996) (Fabre and Hurt, 1997). Perhaps VCP regulates nucleocytoplasmic 
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shuttling of additional proteins, including TDP-43, and that disease mutations impair this 
activity. A third possibility relates to the recently discovered role of VCP in autophagy, 
and the finding that disease-causing mutations in VCP impair autophagy (Ju and Weihl 
2010; Tresse et al. 2010). Since autophagy may be important for turnover of cytoplasmic 
TDP-43 (Wang et al. 2010), accumulation of TDP-43 in the cytoplasm may simply reflect 
a defect in this degradation pathway. These three possibilities are not mutually 
exclusive and it is also possible that redistribution of TDP-43 in IBMPFD reflects defects 
in VCP functions that are presently unknown. 
The present study shows that degeneration initiated by mutations in VCP is 
mediated in part through toxic gain-of-
function of TDP-43 in the cytoplasm. The 
basis for toxicity associated with excess 
cytoplasmic TDP-43 is unclear, but this 
observation is consistent with the recent 
report showing that (1) cytoplasmic 
mislocalization of TDP-43 is toxic to 
neurons and (2) mutations in TDP-43 
that cause familial ALS promote 
cytoplasmic mislocalization (Barmada et al. 2010). There is some evidence to suggest 
that TDP-43, or a fragment of TDP-43, is intrinsically prone to aggregation resulting in 
the formation of a toxic species (Johnson et al. 2009; Zhang et al. 2009). Indeed, we 
have observed a correlation between TDP-43 toxicity in vivo and the presence of TDP-43 
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cleavage products or high molecular weight species of TDP-43 (Fig. 2.5, S2.4-6), although 
this study does not address whether there is a cause and effect relationship between 
these abnormal species and toxicity. Whether or not TDP-43 aggregation promotes 
toxicity, we are particularly intrigued by the possibility that excess cytoplasmic TDP-43 
perturbs some aspect of cytoplasmic RNA metabolism. The notion that a defect in RNA 
metabolism contributes to IBMPFD pathogenesis is supported in the present study by 
the identification of xl6 (the Drosophila ortholog of human SR protein 9G8) and Hrb27C 
(the fly ortholog of the human hnRNP DAZAP1) as dominant modifiers of mutant-VCP 
toxicity in vivo. This notion is further supported by the high frequency with which 
inherited neurodegenerative diseases are caused by mutations that impair RNA 
metabolism, either through mutations in RNA-binding proteins or through mutations in 
RNA that impair the function of RNA binding proteins (Cooper et al. 2009; La Spada and 
Taylor 2010). The extent to which perturbation in RNA metabolism contributes to TDP-
43 proteinopathies in general and IBMPFD in particular, will be fascinating to learn as 
the field moves forward.  
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CHAPTER 3 
 
Genetic Screening of a Drosophila Model of IBMPFD Identifies Ube4b as a Dominant 
Modifier of Toxicity Associated With Mutations in VCP 
Gillian P Ritson, Jake Guinto, Jennifer Moore, Natalia Nedelsky and J. Paul Taylor 
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ABSTRACT 
Mutations in VCP are causative of degenerative disease that can affect muscle, 
brain and bone. Despite VCP being implicated in many major pathways in the cell, the 
mechanism of IBMPFD pathogenesis is unknown. In order to identify novel molecular 
pathways of VCP mutation-dependent degeneration we performed an F1 genetic screen 
using a previously characterized Drosophila model of IBMPFD. We identified four 
proteins that dominantly suppressed degeneration; one of these was Ube4b, a known 
binding partner of VCP. In vitro studies demonstrate that binding of Ube4b to mutant 
VCP is enhanced. These findings suggest that imbalanced adaptor binding of VCP could 
underlie IBMPFD pathogenesis and potentially of other proteinopathies involving VCP 
and its binding partners. 
  
59 
INTRODUCTION 
Frontotemporal dementia with inclusion body myopathy and Paget’s disease of 
bone (IBMPFD) is an autosomal dominant disorder caused by mutations in valosin-
containing protein (VCP) (Watts et al. 2004). VCP, a member of the AAA-ATPase gene 
superfamily is associated with a wide variety of cellular activities (Woodman 2003). VCP 
forms a homohexamer that binds to multiple ancillary proteins associated with 
ubiquitin-dependent processes predominantly via the N-domain. This allows VCP to bind 
to polyubiquitin chains and extract ubiquitinated proteins from multiprotein complexes. 
The CNS pathology of IBMPFD is characterized by ubiquitin-positive inclusions in 
affected brain regions. However only rare inclusions were detected with antibodies to 
VCP and there was no biochemical alteration in the VCP protein (Forman et al. 2006). 
Thus, the data supports the hypothesis that VCP mutations lead to either a dominant 
loss or alteration of a known VCP function, or gain of an as yet undetermined toxicity 
that culminates in the accumulation of ubiquitin conjugates. 
To study the mechanism of VCP-mediated degeneration, we have previously 
established a cell culture model system. Overexpression of mutant, but not wild type 
(WT) VCP leads to a mutation- and time-dependent cellular toxicity. To study VCP-
mediated toxicity in vivo, we developed a Drosophila model recapitulating features of 
IBMPFD utilizing the UAS/Gal4 inducible system to express WT and mutant TER94, 
hereafter referred to as dVCP. Notably, VCP is highly conserved across species, and the 
mutations identified in IBMPFD are conserved amino acids in Drosophila. When 
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expressed in the fly eye, we observed a moderate degenerative phenotype (rough eye) 
with mutant dVCP R152H but not WT (Ritson et al. 2010). 
Drosophila melanogaster is a powerful genetic system. Since first used to model 
expanded polyglutamine-related disease (Warrick et al. 1998), Drosophila have been 
used extensively to provide insights into neurodegenerative and neuromuscular 
diseases. One of the tools used to allow rapid genetic investigation of these models is 
that of genetic screening. Genetic screens have provided valuable information related to 
the molecular mechanisms of disease and have identified novel therapeutic targets in 
many Drosophila models of neurodegenerative and neuromuscular diseases (Pandey et 
al. 2007; Garcia-Lopez et al. 2008; Suzuki et al. 2009). Of particular use is examining the 
effect of modifying genes in the fly eye. The Drosophila eye is a highly repetitive 
structure unnecessary for viability or fertility but allows for the inspection of subtle 
phenotypes. The moderate rough eye phenotype that results from expression of dVCP 
R152H allows for identification of enhancers and suppressors. 
An unbiased approach to identify the molecular mechanism of IBMPFD 
pathogenesis is particularly useful. VCP is involved in a diverse array of activities, many 
of which we may not know and genetic screening has the potential to uncover 
unanticipated pathways. The Drosophila genome contains almost 14000 genes, too 
many to interrogate individually by RNAi. Therefore, the historical approach has been to 
use collections of deficiency lines like the Bloomington Deficiency Kit (Bloomington 
Drosophila Stock Center, Indianapolis, IN). This kit is comprised of ~270 lines of flies that 
contain chromosomal deficiencies covering ~80% of the Drosophila genome. The major 
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limitation to this approach is that the individual modifying gene cannot be identified. In 
order to overcome the problems of the individual methods (RNAi and deficiency 
screening), we decided to combine the two approaches. First, we performed an F1 
genetic screen using the Bloomington kit. Interactors were identified by monitoring 
enhancement or suppression of the rough eye phenotype in F1 transheterozygotes 
using light stereomicroscopy. Once modifiers were identified in the primary screen, we 
filtered out those that failed to show disease-specificity. Subsequently, we validated hits 
and narrowed the candidate regions using multiple overlapping deficiency lines that 
spanned smaller chromosomal regions. Candidate genes within intervals of interest 
were subsequently examined one by one with in vivo RNAi screening. The genes 
identified and the work to characterize them is described in this study. 
 
MATERIALS AND METHODS 
Plasmids 
The generation of pUAST dVCP R152H and FLAG-tagged VCP WT and R155H were 
described in Ritson et al., 2010. To generate pUAST Ube4b, cDNA was obtained from 
Berkeley Drosophila Genome Project and subcloned into pUAST. pCMV-XL6 UBE4B 
cDNA was obtained from Origene. 
Fly culture 
All Drosophila stocks were maintained on standard media in 25oC incubators. All 
deficiency and driver lines were obtained from the Bloomington Stock Center 
(Indianapolis, IN). Double-strand RNAi lines targeting Ube4b (ID36464), TBPH (ID38377), 
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xl6 (ID31202) and Hrb27C (ID16040) were obtained from the Vienna Drosophila RNAi 
Center. The generation of transgenic flies expressing dVCP R152H was described in 
Ritson et al., 2010.  
 
Dominant modifier screen 
Deficiency (Df) lines for all four chromosomes obtained from the Bloomington 
stock center were used to identify dominant modifiers of mutant dVCP in a genetic 
screen. For the primary screen, balanced virgin female dVCP R152H (recombined with 
Gmr GAL4) flies were crossed with Df/Balancer males from ~270 deficiency lines and 
progeny were examined and scored on a twenty-point scale for changes in eye 
phenotype. Eyes were examined for the presence of: supernumerary inter-ommatidial 
bristles (IOBs), IOBs with abnormal orientation, necrotic patches, a decrease in size, 
retinal collapse, fusion of ommatidia, disorganization of ommatidial array and loss of 
pigmentation. Points were added if: there was complete loss of IOBs (+1), more than 3 
small or 1 large necrotic patch (+1), retinal collapse extended to the midline of the eye 
(+1) or beyond (+2), loss of ommatidial structure in less than 50% (+1) or more than 50% 
(+2) of the eye, if pigmentation loss resulted in change of eye color from red to orange 
(+1) or pale orange/white  (+2) and if the coexpression of mutant dVCP and the 
deficiency caused pre-adult lethality at 25C but not 22C (+2). A maximum score of 
twenty was ascribed if the combination was lethal at all temperatures. Gmr, GAL4, UAS 
dVCP R152H / Balancer served as an internal control. In a secondary screen to filter 
nonspecific modifiers of cell death, deficiencies defined as hits (either enhancing or 
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suppressing the dVCP mutant phenotype) were crossed with flies expressing the pro-
apoptotic gene Reaper (recombined with Gmr GAL4). Any hits that similarly affected 
dVCP R152H and Reaper in the secondary screen were excluded from further study due 
to the possibility of non-specific anti-apoptotic effects. As regions of interest were 
identified from the primary and secondary screens, additional Df lines were obtained 
that overlapped with interacting deficiencies to verify and refine the position of 
potential modifiers.  For the final step of gene identification, individual RNAi lines 
corresponding to the genes within the candidate intervals were obtained from the 
Vienna Drosophila RNAi Center. Gmr GAL4, UAS dVCP R152H females were crossed with 
males from the RNAi lines and the progeny eyes were evaluated for changes. A modifier 
was defined as an RNAi line that replicated the enhancement or suppression of the 
corresponding deficiency. 
 
Cell culture and transfection 
HEK293T cells were seeded in 6-well dishes and grown in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 1% penicillin-
streptomycin, and 1% L-glutamate. HEK293T cells were transfected with 2ug of each of 
the combinations of the plasmids encoding the indicated transgenes using FuGene 6 
(Roche Applied Sciences) according to the manufacturer’s protocol. After 48h, cells were 
harvested in lysis buffer, immunoprecipitated overnight at 4C with -FLAG (M2) agarose 
beads (Sigma), resolved by 4-15% SDS-PAGE, transferred to nitrocellulose membrane 
(Biorad) and immunoblotted with primary antibodies 1:1000 -FLAG (M2) (Sigma) and 
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1:1000 -UBE4B (Novus). Primary antibodies were detected with horseradish 
peroxidase-conjugated anti-rabbit IgG (Jackson ImmunoResearch) and proteins were 
visualized using Immobilon Western Chemiluminescent AP Substrate (Millipore). Band 
intensities were analyzed from film by Kodak Imager software (Kodak). 
 
Real-time quantitative PCR 
Total RNA was isolated from 10 animals of the appropriate genotype with TRIzol 
reagent (Invitrogen) and cDNA was generated using the iScript cDNA Synthesis kit 
(BioRad) following the manufacturer’s protocol. The concentration of each primer probe 
set was individually optimized. Quantitative real-time PCR reactions were carried out in 
a total reaction volume of 25 ul of iQ Supermix (BioRad) using BioRad iCycler iQ5. 
Transcript levels were normalized to dGAPDH2. The primer/probe set for genes 
purchased from Applied Biosystems were as follows: Hrb27C-- Dm01803323_g1, xl6--
Dm01803314_m1, TBPH--Dm01820181_g1 and GAPDH2 ctl.--Dm01843776_S1. 
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RESULTS 
A dominant modifier screen identifies multiple regions of the Drosophila genome that 
modify mutant dVCP toxicity 
VCP participates in a 
range of cellular activities and 
thus in diverse biological 
pathways. The pathways 
affected by disease-associated 
mutations in VCP are unknown. 
The highly organized 
arrangement of ommatidia in the 
Drosophila eye facilitates the 
identification of genes that 
regulate pathways involved in 
the degenerative phenotype 
associated with VCP mutations. 
We have previously developed 
an in vivo model of VCP-mediated degeneration by introducing the R152H mutation into 
the highly conserved conserved Drosophila VCP orthologue dVCP, homologous to the 
R155H mutation that causes the most common form of IBMPFD (Ritson et al. 2010). 
When expressed in the fly eye using the driver Gmr GAL4, dVCP R152H leads to a 
moderate rough eye phenotype (Fig 3.1A). As an unbiased approach to identify 
66 
modulators of the phenotype associated with mutant dVCP, we performed an F1 
genetic screen using the moderate dVCP mutant crossed to Bloomington Deficiency Kit 
(Bloomington Drosophila Stock Center, Indianapolis, IN). This deficiency kit contains 
~270 lines of flies that contain chromosomal deficiencies covering ~80% of the 
Drosophila genome (Fig 3.1B). Interactors were identified by monitoring enhancement 
or suppression of the rough eye phenotype in F1 transheterozygotes using light 
stereomicroscopy. From the primary screen, seventy-four deficiencies were identified as 
enhancers or suppressors of the dVCP R152H phenotype (Table 3.1). In order to quantify 
the phenotypic change, adult eyes were scored for the presence of changes in 
characteristics such 
as gross structure 
and pigment (Fig 
3.1C). Based on these 
scores, fifty-four hits 
were identified as 
dominant modifiers; 
thirty-one 
suppressors and 
twenty-three 
enhancers including two lines which were lethal when combined with mutant dVCP (Fig 
3.2).            
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Secondary screens and individual gene assessment identifies multiple individual 
modifiers of mutant dVCP toxicity  
The advantage of the Bloomington Deficiency Kit is that it spans a majority of the 
Drosophila genome in relatively few lines. However, the resulting gene regions covered 
by the hits from the primary screen still represent a significant portion of the genome. 
68 
Therefore, secondary screening measures were necessary to reduce the number of hits 
to examine further. One concern 
was that modifiers within regions 
of interest were affecting the 
apoptotic pathway and causing 
changes in the phenotype that 
were not disease-specific. To this 
end, we expressed Reaper in the 
eye in the background of the 
deficiencies identified in the 
primary screen. Reaper is a pro-
apoptotic gene whose expression 
leads to the initiation of 
programmed cell death (White et 
al. 1994). Therefore, any 
deficiencies which similarly 
affected Reaper were excluded 
from the study as not disease-
specific. To date ~80% of the hits 
have been thus tested and results 
are summarized in Table 3.1. Thirty-one hits remained following the secondary screen 
and from these the strongest three suppressors and enhancers were chosen for further 
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study (Fig 3.3A). No external phenotype was seen when these deficiency lines were co-
expressed with the control UAS LacZ using Gmr GAL4. This demonstrated that the 
change seen in the dVCP phenotype was not due to the deficiencies either having a 
phenotype themselves or though an interaction with the UAS GAL4 system (Fig 3.3B). 
The deficiencies within the Bloomington Kit are mapped cytologically, a method 
based on approximating breakpoints through microscopic examination of polytene 
chromosomes. Due to possible imprecision, innacuracies or unidentified secondary 
breakpoints, we validated the top deficiencies using overlapping deficiencies from other 
kits (or from the original results). Those deficiencies which similarly affected the mutant 
dVCP toxicity acted both to validate the original hit and also to define the region of 
interest (Fig 3.3C-D).  
Where possible, the genes remaining within the regions of interest were then 
interrogated individually using double-strand RNAi lines (Vienna Drosophila RNAi 
Center, Vienna Austria). From three of the suppressor lines (Df(2L)BSC30, Df(2L)Dwee1-
W05, and Df(2R)BSC136), we identified four genes as dominant modifiers of the mutant 
dVCP toxicity  (Ube4b, xl6 and Hrb27C, and TBPH) (Fig 3.4A). No external phenotype was 
seen when these lines are expressed alone in the eye despite significant reduction in 
expression (Fig 3.4B-C). 
 
Ube4b is verified as a dominant modifier of toxicity associated with disease-related 
mutations in dVCP 
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  As discussed in chapter II, the RNA-
binding proteins xl6 and Hrb27C were verified 
as hits by using additional RNAi lines and 
classical alleles (Figure S2.2E-F). We also 
generated transgenic lines over-expressing 
TBPH, which resulted in a degenerative 
phenotype evident externally and 
histologically. In a similar manner, due to the 
lack of alternate alleles with which to validate 
Ube4b, we generated transgenic lines over-
expressing Ube4b. When expressed in the 
eye, exogenous Ube4b does not cause 
toxicity despite high levels of overexpression 
(Fig 3.5A-B). However, when co-expressed 
with dVCP R152H in the eye, Ube4b 
significantly enhances the toxicity associated 
with mutant dVCP. In combination with the 
complementary data that a reduction in 
Ube4b suppresses the mutant dVCP toxicity, 
this validates Ube4b as a dominant modifier 
of the toxicity associated with disease-related 
mutations in dVCP.  
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Exogenous expression of mutant VCP leads to greater binding of Ube4b 
Ube4b (ubiquitination factor E4B), also known as UFD2 (ubiquitin-fusion 
degradation protein 2) is a highly conserved ubiquitin-binding protein that influences 
the ubiquitin conjugation reaction of long multiubiquitin chains (Koegl et al. 1999). 
Ube4b is known to associate with VCP to extend short ubiquitin chains on proteins 
targeted for degradation; likely 
increasing their recognition as a 
degradative target by the 
proteasome (Richly et al. 2005). To 
examine the effect of disease-
related mutations in VCP on the 
binding to the confirmed disease 
modifier and known binding 
partner Ube4b, we transiently co-
expressed human UBE4B and 
FLAG-tagged VCP WT and R155H 
in HEK293T cells. From lysates 
prepared from these cells, we immunoprecipitated FLAG and probed for UBE4B (Fig 
3.6A).  Quantitation of the band intensities from four pooled trials showed that when 
measured relative to FLAG (VCP) immunoprecipitated, VCP R155H bound to more 
UBE4B than WT VCP in vitro (Fig 3.6B).  
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DISCUSSION 
In a Drosophila model of IBMPFD developed in our lab, we performed an F1 
genetic screen to identify dominant modifiers of toxicity associated with disease-related 
mutations in VCP. From the primary screen, seventy-four deficiencies were identified by 
light microscopy as modifying the dVCP R152H eye phenotype (Table 3.1). Of these, 
sixty-three were validated by a quantitative scoring method as dominant modifiers 
(enhancers or suppressors) (Fig 3.2). After the secondary screen, validation studies, and 
individual gene interrogation by double-strand RNAi lines, we identified four genes that 
dominantly suppress the degenerative phenotype (Fig 3.4). TBPH (CG10327), xl6 
(CG10203) and Hrb27C (CG10377) are RNA-binding proteins while Ube4b (CG9934) is a 
known binding partner of VCP (Koegl et al. 1999). In order to validate Ube4b as a 
modifier, we generated transgenic lines over-expressing Ube4b (Fig 3.5A-B). When co-
expressed with mutant dVCP, the toxicity associated with mutant VCP is enhanced. 
When studied in vitro, we found that the binding of VCP to Ube4b was altered, mutant 
VCP bound to more Ube4b than WT VCP. Together, our results show that Ube4b is a 
dominant modifier of toxicity associated with disease-related mutations in VCP 
potentially because of altered binding between mutant VCP and its adaptor. 
Ube4b, also known as UFD2, was originally described as a ubiquitin chain 
assembly factor (E4) in the U-box containing ubiquitin-fusion degradation (UFD) family. 
E4 activity is thought to reflect a specialized ubiquitin-protein ligase (E3) activity 
targeting previously ubiquitinated proteins for further ubiquitination. The physiological 
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significance of this activity was unclear but insights gained from identifying targets of 
Ube4b have proven valuable. VCP has long been implicated in the UFD pathway 
(Johnson et al. 1995) and is now known to form a functional complex with Ube4b in 
order to regulate the degradation of target proteins such as Unc45b (Janiesch et al. 
2007).  A recent study demonstrated that IBMPFD-mutations are defective in the 
degradation of Unc45b but no comment was made to the effect on Ube4b binding 
(Janiesch et al. 2007). Our study reveals an increased binding of mutant VCP to Ube4b 
(Fig 3.6). This is in contrast to work recently published, and done in the same cell 
system, where the authors claim that expression of disease-associated  VCP mutants 
lead to an reduced binding of Ube4b (Fernandez-Saiz and Buchberger 2010). Their study 
evaluated endogenous Ube4b which we were unable to detect (Fig 3.6A). Interestingly 
they found that increasing expression of other known adaptors affected the binding of 
Ube4b to mutant VCP presumably through competition for sites on the VCP hexamer. 
Our study overexpressed Ube4b, thereby eliminating competition for binding. Both 
studies highlight that IBMPFD-mutations cause a change in the binding profile of VCP 
potentially trapping VCP in unproductive or overproductive co-factor complexes. This is 
turn could impact multiple, distinct cellular functions of VCP. The finding that a 
reduction in Ube4b expression leads to a suppression of the toxicity associated with 
mutant VCP (Fig 3.4A) could suggest a re-balancing of the cofactor profile and VCP 
functional pathways, though further studies are required to address this. 
The hypothesis that formation of altered VCP/adaptor complexes lead to disease 
pathogenesis could have implications for other proteinopathies caused by mutations in 
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known VCP co-factors. Indeed, just as mutant VCP shows increased binding to ataxin-3 
(Fernandez-Saiz and Buchberger 2010), ataxin-3 with pathological polyglutamine 
expansions; causative of Machado-Joseph’s Disease; shows enhanced binding to VCP  
that actually decreases with smaller polyglutamine tracts (Matsumoto et al. 2004). 
Mutant VCP is also known to amplify the NF- B activation presumably through altered 
regulation of I B-  ubiquitin-dependent degradation (Custer et al. 2010). Amplification 
of the NF-kB signaling pathway has been previously identified as the molecular defect 
underlying multiple genetic forms of Paget’s disease of bone (Soysa and Alles 2009). 
Therefore, understanding the functional network and maintaining the appropriate 
balance of VCP’s functions could yield insight into the broad array of proteinopathies 
that result from mutations in VCP and its multiple binding partners. 
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Table 3.1: Results from Primary and Secondary (Reaper) Deficiency Screens to Identify 
Dominant Modifiers of Mutant dVCP-Associated Toxicity 
DEFICIENCY CYTOLOGY dVCP 
R152H 
REAPER 
Df(1)BA1, w*/FM7a; Dp(1;2)E1, y+/+ 1A1:2A NC  
Ts(1Rt;3Lt)scJ4, scJ4C(1)DX, y1f1;Dp(1;f)z9,y+  1B2-14;3A3 NC  
Df(1)64c18, g[1] sd[1]/Dp(1;2;Y)w[+]/C(1)DX, y[1]  2E1-2;3C2 S S 
Df(1)JC19/FM7c 2F6;3C5 NC  
Df(1)N-8/FM7c 3C2-3;3E3-4 E  
Df(1)dm75e19/FM7c 3C11;3E4 NC  
Df(1)A113/C(1)DX, y[1] w[1] f[1]; 
Dp(1;2)w[+]64b/+ 
3D6-E1;4F5 NC  
Df(1)JC70/FM7c, sn[+] 4C15-16;5A1-2 NC  
Df(1)C149/FM6 5A8-9;5C5-6 NC  
Df(1)N73/FM6  5C2;5D5-6 NC  
Df(1)dx81, w[*]/Dp(1;Y)dx[+]1/C(1)M5 5C3-10;6C3-12 E  
Df(1)ED6878, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED6878/FM7
h 
6C12;6D8 NC  
Df(1)ct-J4, In(1)dl-49, f[1]/C(1)DX, y[1] w[1] f[1]; 
Dp(1;3)sn[13a1]/+ 
7A2-3;7C1 NC  
Df(1)ct4b1, y[1]/Binsn 7B2-4;7C3-4 NC  
Df(1)C128/FM6 7D1;7D5-6 E  E  
Df(1)RA2/FM7c 7D10;8A4-5 E  NC 
Df(1)KA14/FM7c 7F1-2;8C6 NC  
Df(1)lz-90b24, y[2] w[a]/FM7c 8B5-6;8D8-9 E  
Df(1)C52, flw[C52]/FM6 8E;9C-D NC  
Df(1)v-L15/FM6 9B1-2;10A1-2 NC  
Df(1)v-N48, f[*]/Dp(1;Y)y[+]v[+]#3/C(1)DX, y[1] 
f[1] 
9F;10C3-5 S   
Df(1)HA85/FM7c 10C1-2;11A1-2 S   
Df(1)N105/FM6 10F7;11D1 NC  
Df(1)C246/FM6 11D-E;12A1-2 NC  
Df(1)g, f[1] B[1]/In(1)AM 12A3-10;12E9 NC  
Df(1)RK2/FM7a 12D2-E1;13A2-
5 
NC  
Df(1)RK4/FM7k/Dp(1;Y)y[+], y[1] 12F5-6;13A9-B1 NC  
In(1)AC2[L]AB[R], y[1] w[1]/FM7c 9D5-E1;9E7-8 + 
13B5-6;13E1-2 
NC  
Df(1)sd72b/FM7a 13F1;14B1 E NC 
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Df(1)XR38, y[1] w[1] f[1]/C(1)DX, y[1] w[1] f[1]; 
Dp(1;4)r[+]/+ 
14A;15D NC  
Df(1)4b18, y[1] cv[1] v[1] nonA[4b18] f[1] 
car[1]/FM0 
14B8;14C1 NC  
Df(1)r-D1, v[1] f[1]/C(1)DX, y[1] f[1]; Dp(1;4)r[+]m 14C5-6;15B1 NC  
Df(1)B25, Sh[14]/FM6 15D3;16A4-6 NC  
Df(1)BK10, r[*] f[1]/FM7c 16A2;16C7-10 NC  
Df(1)RR79, w[1118]/FM7a 16C;16F NC  
Df(1)N19/FM6 17A1;18A2 
 
NC  
Df(1)Exel6291, w[1118] P{w[+mC]=XP-
U}Exel6291/FM7c 
17F3;18A2 NC  
Df(1)JA27/FM7c 18A5;18D NC  
Df(1)Exel6253, w[1118] P{w[+mC]=XP-
U}Exel6253/FM7c 
18D13;18F2 NC  
Df(1)DCB1-35b/FM6/Dp(1;Y)y[+]mal[106], 
mal[106] 
19F1-2;20E-F NC  
Df(1)A209/FM7a 20A;20F NC  
Df(2L)net-PMF/SM6a 21A1;21B7-8 NC  
Df(2L)BSC4, w[+mC], net[1] cn[1]/SM5 21B7-C1;21C2-3 NC  
Df(2L)BSC16, net[1] cn[1]/SM6a 21C3-4;21C6-8 NC  
Df(2L)ast2/SM1 21D1-2;22B2-3 S E 
Df(2L)dp-79b, dp[DA] cn[1]/In(2LR)bw[V1], b[1] 
bw[V1] 
22A2-3;22D5-
E1 
NC  
Df(2L)BSC37/CyO 22D2-3;22F1-2 E NC 
Df(2L)dpp[d14]/In(2LR)Gla, wg[Gla-1] 22E4-F2;22F3-
23A1 
NC  
Df(2L)C144, dpp[d-ho] ed[1]/In(2LR)Gla, wg[Gla-1] 
Bc[1] Egfr[E1] 
22F4-
23A1;23C2-4 
S S 
Df(2L)JS17, dpp[d-ho]/CyO, 
P{ry[+t7.2]=en1}wg[en11] 
23C1-2;23E1-2 NC  
Df(2L)BSC28/SM6a, bw[k1] 23C5-D1;23E2 NC  
Df(2L)BSC31, net[1] cn[1]/CyO, b[81f2] rk[81f2] 23E5;23F4-5 NC  
y[1] w[*]; Df(2L)drm-P2, 
P{w[+mC]=lacW}Pdsw[k10101]/SM6b 
23F3-4;24A1-2 NC  
Df(2L)ed1/CyO; P{ry[+t7.2]=ftz/lacC}1 24A2;24D4 NC  
w[1118]; Df(2L)ED250, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED250/SM6a 
24F4;25A7 NC  
w[1118]; Df(2L)BSC110, 
P+PBac{XP5.RB3}BSC110/CyO 
25C1;25C3 NC  
w[1118]; Df(2L)BSC109, 
P+PBac{XP5.RB3}BSC109/CyO 
25C4;25C8 NC  
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w[1118]; Df(2L)Exel6011, P{w[+mC]=XP-
U}Exel6011/CyO 
25C8;25D5 E NC 
Df(2L)cl-h3/SM6b 25D2-4;26B2-5 NC  
In(1)w[m4]; Df(2L)E110/CyO 25F3-
26A1;26D3-11 
NC  
Df(2L)BSC5, w[+mC]/SM6a 26B1-2;26D1-2 NC  
Df(2L)BSC6, dp[ov1] cn[1]/SM6a 26D3-E1;26F4-7 S  
w[1118]; Df(2L)BSC7/CyO 26D10-E1;27C1 NC  
w[*]; Df(2L)spd[j2], wg[spd-j2]/CyO, 
P{ry[+t7.2]=ftz/lacB}E3 
27C1-2;28A NC  
w[*]; Df(2L)Dwee1-W05/CyO; 
P{ry[+t7.2]=ftz/lacC}1 
27C2-3;27C4-5 S  NC 
Df(2L)XE-3801/CyO, P{ry[+t7.2]=sevRas1.V12}FK1 27E2;28D1 NC  
Df(2L)BSC41, dp[ov1] cn[1]/CyO 28A4-B1;28D3-
9 
NC  
w[1118]; Df(2L)BSC142, 
P+PBac{XP5.WH5}BSC142/CyO 
28C3;28D3 NC  
y[1] w[67c23]; Df(2L)Trf-C6R31/CyO 28DE;28DE NC  
In(1)w[m4h], y[1]; Df(2L)TE29Aa-11, dp[*]/CyO 28E4-7;29B2-C1 NC  
w[1118]; Df(2L)BSC111, 
P+PBac{XP5.WH5}BSC111/CyO 
28F5;29B1 NC  
w[1118]; Df(2L)ED611, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED611/SM6a 
29B4;29C3 NC  
Df(2L)N22-14/CyO 29C1-2;30C8-9 NC  
Df(2L)BSC17/SM6a 30C3-5;30F1 NC  
Df(2L)Mdh, cn[1]/Dp(2;2)Mdh3, cn[1] 30D-30F;31F NC  
Df(2L)BSC50/SM6a 30F4-5;31B1-4 NC  
y[*]; Df(2L)J2/SM1 31B;32A E S 
w[1118]; Df(2L)BSC143, 
P+PBac{XP5.WH5}BSC143/CyO 
31B1;31D9 NC  
Df(2L)BSC32/SM6a, bw[k1] 32A1-2;32C5-
D1 
NC  
w[1118]; Df(2L)BSC145, 
P+PBac{XP5.WH5}BSC145/CyO 
32C1;32C5 NC  
Df(2L)BSC36/SM6a, bw[k1] 32D1;32D4-E1 NC  
Df(2L)FCK-20, dp[ov1] bw[1]/CyO, 
P{ry[+t7.2]=sevRas1.V12}FK1 
32D1;32F1-3 E E 
Df(2L)Prl, Prl[1] nub[Prl]/CyO 32F1-3;33F1-2 NC  
Df(2L)BSC30/SM6a, bw[k1] 34A3;34B7-9 S NC 
Df(2L)BSC159, 
P+PBac{XP5.WH5}BSC159/Dp(2;2)Cam5, bw[1] 
sp[1] 
34B4;34C4 E NC 
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Df(2L)b87e25/CyO 34B12-
C1;35B10-C1 
NC  
w[1118]; Df(2L)BSC147, 
P+PBac{XP5.RB3}BSC147/CyO 
34C1;34C6 NC  
Df(2L)TE35BC-24, b[1] pr[1] pk[1] cn[1] sp[1]/CyO 35B4-6;35F1-7 NC  
Df(2L)r10, cn[1]/CyO 35D1;36A6-7 NC  
Df(2L)cact-255rv64, cact[chif64]/CyO; ry[506] 35F-36A;36D NC  
Df(2L)TW137, cn[1] bw[1]/CyO, Dp(2;2)M(2)m[+] 36C2-4;37B9-C1 E  NC 
Df(2L)pr-A16, cn[1] bw[1]/CyO 37B2-12;38D2-
5 
NC  
Df(2L)TW161, cn[1] bw[1]/CyO 38A6-B1;40A4-
B1 
NC  
w[1118]; Df(2L)Exel6049, P{w[+mC]=XP-
U}Exel6049/CyO 
39E7;40D3 NC  
w[1118]; Df(2L)BSC151, 
P+PBac{XP5.WH5}BSC151/CyO 
40A5;40E5 NC  
Df(2L)C'/CyO h35;h38L NC  
In(2R)bw[VDe2L]Cy[R]/In(2LR)Gla, wg[Gla-1] h42-h43;42A2-3 NC  
Df(2R)M41A4/SM1 41A;41A NC  
Df(2R)nap9/Dp(2;2)BG, In(2LR)Gla, wg[Gla-1] 42A1-2;42E6-F1 NC  
Df(2R)ST1, Adh[n5] pr[1] cn[*]/CyO 42B3-5;43E15-
18 
E  E  
Df(2R)cn9/CyO, amos[Roi-1] sp[*] 42E;44C NC  
w[118]; Df(2R)H3C1/CyO 43F;44D3-8 S  NC 
w[118]; Df(2R)H3E1/CyO 44D1-4;44F12 NC  
w[1]; Df(2R)Np5, In(2LR)w45-32n, cn[1]/CyO 44F10;45D9-E1 E NC 
w[1]; Df(2R)w45-30n, cn[1]/CyO 45A6-7;45E2-3 NC  
Df(2R)BSC29, cn[1] bw[1] sp[1]/CyO 45D3-4;45F2-6 S  E  
w[1118]; Df(2R)BSC132, 
P+PBac{XP5.WH5}BSC132/SM6a 
45F6;46B12 NC  
w[1118]; Df(2R)B5, px[1] sp[1]/CyO, Adh[nB] 46A;46C NC  
Df(2R)X1, Mef2[X1]/CyO, Adh[nB] 46C;47A1 NC  
Df(2R)en-A/CyO 47D3;48B2 NC  
Dp(1;Y)B[S]; Df(2R)en30/SM5 48A3-4;48C6-8 NC  
Df(2R)BSC39, cn[1] bw[1]/SM6a, bw[k1] 48C5-D1;48D5-
E1 
NC  
Df(2R)CB21/CyO; ry[506] 48E;49A NC  
Df(2R)BSC40/SM6a 48E1-2;48E2-10 S  NC 
D(2R)BSC3, w[+mC] unch[k15501] cn[1] bw[1] 
sp[1]/SM6a, bw[k1] 
48E12-
F4;49A11-B6 
NC  
Df(2R)vg-C/CyO, P{ry[+t7.2]=sevRas1.V12}FK1 49A4-13;49E7-
F1 
NC  
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Df(2R)CX1, wg[12] b[1] pr[1]/SM1 49C1-4;50C23-
D2 
NC  
Df(2R)BSC18/SM6a 50D1;50D2-7 NC  
w[1118]; Df(2R)Exel7130, 
P+PBac{XP5.WH5}Exel7130/CyO 
50D4;50E4 NC  
Df(2R)BSC134, 
P+PBac{XP5.WH5}BSC134/Dp(2;3)Cam14T 
50E1;50E6 E  
w[1118]; Df(2R)Exel7131, 
P+PBac{XP5.WH5}Exel7131/CyO 
50E4;50F6 NC  
Df(2R)BSC11/SM6a 50E6-F1;51E2-4 NC  
w[a] N[fa-g]; Df(2R)Jp1/CyO 51D3-8;52F5-9 S E 
w[a] N[fa-g]; Df(2R)Jp8, w[+]/CyO 52F5-9;52F10-
53A1 
NC  
Df(2R)BSC49/SM6a 53D9-E1;54B5-
10 
NC  
Df(2R)BSC44/SM6a 54B1-2;54B7-10 NC  
w[1118]; Df(2R)BSC161, 
P+PBac{XP5.WH5}BSC161/CyO 
54B2;54B17 NC  
Df(2R)robl-c/CyO, y[+] 54B17-C4;54C1-
4 
NC  
y[1] w[67c23]; Df(2R)k10408, 
P{w[+mC]=lacW}mthl3[k10408] CG4827[k10408] 
/CyO 
54C1-4;54C1-4 NC  
Df(2R)BSC45, w[+mC]/SM6a 54C8-D1;54E2-
7 
NC  
y[1] w[67c23]; Df(2R)14H10Y-53/SM6a 54D1-2;54E5-7 S NC 
y[1] w[67c23]; Df(2R)14H10W-35/SM6a 54E5-7;55B5-7 NC  
Df(2R)PC4/CyO 55A;55F E NC 
y[1] w[*]/Dp(1;Y)y[+]; Df(2R)P34/CyO 55E2-4;56C1-11 S NC 
Df(2R)BSC26/CyO 56C4;56D6-10 NC  
Df(2R)BSC22/SM6a 56D7-E3;56F9-
12 
NC  
Df(2R)AA21, c[1] px[1] sp[1]/SM1 56F9-17;57D11-
12 
E NC 
w[1118]; Df(2R)Exel7162, 
P+PBac{XP5.WH5}Exel7162/CyO 
56F11;56F16 E NC 
Df(2R)BSC19, cn[1] bw[1]/SM6a 56F12-14;57A4 NC  
Df(2R)Egfr5, b[1] pr[1] cn[1] sca[1]/CyO, 
P{ry[+t7.2]=sevRas1.V12}FK1 
57D2-8;58D1 NC  
Dp(1;Y)y[+]/y[1]; Df(2R)X58-12/SM5 58D1-2;59A NC  
w[*]; Df(2R)59AD/SM1 59A1-3;59D1-4 E NC 
Df(2R)vir130/CyO 59B;59D8-E1 NC  
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Df(2R)or-BR6, cn[1] bw[1] 
sp[1]/In(2LR)lt[G16L]bw[V32gR], bw[V32g] 
59D5-10;60B3-
8 
NC  
w[1118]; Df(2R)BSC136/SM6a 59F5;60B6 S NC 
w[1118]; Df(2R)BSC155, 
P+PBac{XP5.WH5}BSC155/CyO, Ts(Y;2Lt)B80, y[+] 
60B9;60C4 NC  
Df(2R)Px2/CyO, P{ry[+t7.2]=sevRas1.V12}FK1 60C5-6;60D9-
10 
S NC 
w[1118]; Df(2R)ED4065, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED4065/SM6
a 
60C8;60E8 E NC 
Df(2R)M60E/In(2LR)bw[V32g], bw[V32g] 60E2-3;60E11-
12 
E NC 
Df(2R)Kr10, b[1] pr[1] Bl[1] c[1]/CyO 60F1;60F5 NC  
Df(3L)emc-E12/TM6B, Tb[1] ca[1] 61A;61D3 NC  
Df(3L)Ar14-8, red[1]/TM2, p[p] 61C5-8;62A8 NC  
w[1118]; Df(3L)Exel6087, P{w[+mC]=XP-
U}Exel6087/TM6B, Tb[1] 
62A2;62A7 NC  
Df(3L)Aprt-1, ru[1] h[1]/TM3, Ser[1] 62A10-
B1;62D2-5 
NC  
w[1118]; Df(3L)BSC181, 
P+PBac{XP5.WH5}BSC181/TM6C, Sb[1] 
62A11;62B7 NC  
Df(3L)R-G7, rho[ve-1]/TM6B, Tb[1] 62B4-7;62D5-
E5 
NC  
Df(3L)BSC23, rho[ve-1] e[1]/TM2, p[p] 62E8;63B5-6 NC  
Df(3L)M21, kni[ri-1] p[p]/In(3LR)T33[L]f19[R], h[1] 
th[1] st[1] cu[1] sr[1] 
62F;63D E NC 
Df(3L)HR119/TM6B, Tb[+] ca[1] 63C2;63F7 E NC 
w[1118]; Df(3L)GN34/TM3, ry[*] su(Hw)[2] Sb[1] 63E6-9;64A8-9 S S 
Df(3L)GN24/TM8, l(3)DTS4[1] 63F6-7;64C13-
15 
NC  
Df(3L)ZN47, ry[506]/TM3, Sb[1] 64C;65C NC  
w[*]; Df(3L)XDI98, e[1]/TM6B, Tb[1] 65A2;65E1 NC  
Df(3L)BSC27/TM6B, Tb[1] 65D4-5;65E4-6 NC  
Df(3L)BSC33, rho[ve-1] e[1]/TM2 65E10-F1;65F2-
6 
NC  
Df(3L)pbl-X1/TM6B, Tb[1] 65F3;66B10 NC  
w[1]; Df(3L)ZP1/TM3, Sb[1] Ser[1] 66A17-20;66C1-
5 
S S 
y[1] w[1] N[spl-1]; Df(3L)66C-G28/TM3, Sb[1] 66B8-9;66C9-10 S S 
Df(3L)BSC13, rho[ve-1] e[1]/TM2, p[p] 66B12-
C1;66D2-4 
NC  
Df(3L)h-i22, h[i22] Ki[1] rn[roe-1] p[p]/TM3, Ser[1] 66D10-11;66E1- NC  
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2 
Df(3L)Scf-R6, th[1] st[1] cu[1] sr[1] e[s] ca[1]/TM3, 
Sb[1] 
66E1-6;66F1-6 S S 
Df(3L)BSC35, rho[ve-1] e[1]/TM3, P{w[+m*]=Ubx-
lacZ.w[+]}TM3, Sb[1] 
66F1-2;67B2-3 S NC 
Df(3L)AC1, rn[roe-1] p[p]/TM3, Sb[1] 67A2;67D11-13 S S 
Df(3L)BSC14, rho[ve-1] p[*] e[1]/TM3, Ser[1] 67E3-7;68A2-6 NC  
Df(3L)vin5, ru[1] h[1] gl[2] e[4] ca[1]/TM3, Sb[1] 
Ser[1] 
68A2-3;69A1-3 NC  
Df(3L)vin7, h[1] gl[2] e[4] ca[1]/TM3, Sb[1] Ser[1] 68C8-11;69B4-5 NC  
w[*]; Df(3L)eyg[C1]/TM3, 
P{ry[+t7.2]=ftz/lacC}SC1, ry[RK] Sb[1] Ser[1] 
69A4-5;69D4-6 NC  
Df(3L)BSC10, rho[ve-1] e[1]/TM3, Ser[1] 69D4-5;69F5-7 NC  
Df(3L)BSC12, rho[ve-1] e[1]/TM3, P{w[+m*]=Ubx-
lacZ.w[+]}TM3, Sb[1] 
69F6-
70A1;70A1-2 
S S 
In(3LR)C190[L]Ubx[42TR], Ubx[-]/sti[1] 70A1-2;70C3-4 S NC 
Df(3L)fz-GF3b, P{w[+tAR] 
ry[+t7.2AR]=wA[R]}66E/TM6B, Tb[+] 
70C1-2;70D4-5 NC  
Df(3L)fz-M21, st[1]/TM6 70D2-3;71E4-5 NC  
Df(3L)XG5/TM3, Sb[1] Ser[1] 71C2-3;72B1-C1 S S 
Df(3L)brm11/TM6C, cu[1] Sb[1] ca[1] 71F1-4;72D1-10 E E  
Df(3L)st-f13, Ki[1] rn[roe-1] p[p]/TM6B, Tb[1] 72C1-D1;73A3-
4 
E E  
Df(3L)81k19/TM6B, Tb[1] 73A3;74F NC  
Df(3L)BSC8/TM3, Ser[1] 74D3-
75A1;75B2-5 
S S 
Df(3L)W10, ru[1] h[1] Sb[sbd-2]/TM6B, Tb[1] 75A6-7;75C1-2 NC  
Df(3L)Cat, kni[ri-1] Sb[sbd-1] e[*]/TM3, Ser[1] 75B8;75F1 NC  
w[1118]; Df(3L)ED4782, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED4782/TM6
C, cu[1] Sb[1] 
75F2;76A1 NC  
w[*]; Df(3L)fz2/TM6B, Tb[1] 75F10-11;76A1-
5 
NC  
Df(3L)BSC20, st[1] ca[1]/TM6B, Tb[1] 76A7-B1;76B4-
5 
NC  
Df(3L)kto2/TM6B, Tb[1] 76B1-2;76D5 S  
Df(3L)XS533/TM6B, Sb[1] Tb[1] ca[1] 76B4;77B S S 
Df(3L)rdgC-co2, th[1] st[1] in[1] kni[ri-1] 
p[p]/TM6C, cu[1] Sb[1] Tb[1] ca[1] 
77A1;77D1 E  
Df(3L)ri-79c/TM3, Sb[1] 77B-C;77F-78A NC  
Df(3L)ri-XT1, ru[1] st[1] e[1] ca[1]/TM3, 
P{w[+m*]=Ubx-lacZ.w[+]}TM3, Sb[1] 
77E2-4;78A2-4 NC  
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Df(3L)ME107, mwh[1] red[1] e[1]/TM1, red[*] 77F3;78C8-9 NC  
Df(3L)Pc-2q, ry[506]/TM2 78C5-6;78E3-
79A1 
E  
w[1118]; Df(3L)ED4978, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED4978/TM6
C, cu[1] Sb[1] 
78D5;79A2 S NC 
w[1118]; Df(3L)BSC223, 
P+PBac{XP5.WH5}BSC223/TM6C, Sb[1] 
79A3;79B3 NC  
w[1118]; Df(3L)BSC249, 
P+PBac{XP5.WH5}BSC249/TM6C, Sb[1] cu[1] 
79B2;79D2 NC  
w[*]; Df(3L)HD1/TM3, Sb[1] Ser[1] 79D3-E1;79F3-6 NC  
Df(3L)BSC21, st[1] sr[1] e[s] ca[1]/TM3, Sb[1] 
Ser[1] 
79E5-F1;80A2-3 NC  
Df(YS)bb[-]; Df(3R)ME15, mwh[1] red[1] 
e[4]/MKRS 
81F3-6;82F5-7 NC  
Df(3R)3-4, ru[1] th[1] st[1]/TM3, Sb[1] Ser[1] 82F3-4;82F10-
11 
NC  
w[*]; Df(3R)e1025-14/TM6B, Tb[1] 82F8-10;83A1-3 NC  
w[1118]; Df(3R)Exel6144, P{w[+mC]=XP-
U}Exel6144/TM6B, Tb[1] 
83A6;83B6 E E 
w[1118]; Df(3R)ED5177, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED5177/TM6
C, cu[1] Sb[1] 
83B4;83B6 NC  
Df(3R)BSC47, st[1] ca[1]/TM3, P{w[+m*]=Ubx-
lacZ.w[+]}TM3, Sb[1] 
83B7-C1;83C6-
D1 
NC  
Df(3R)Tpl10, Dp(3;3)Dfd[rv1], kni[ri-1] Dfd[rv1] 
p[p] Doa[10]/TM3, Sb[1] 
83C1-2;84B1-2 S NC 
Df(3R)WIN11, Ki[1] rn[roe-1] p[p]/TM3, Sb[1] 83E1-2;84A5 NC  
Df(3R)Scr, p[p] e[s]/TM3, Sb[1] 84A1-2;84B1-2 S S 
Df(3R)Antp17/TM3, Sb[1] Ser[1] 84A5;84D9 S  
Df(3R)p712, red[1] e[1]/TM3, Sb[1] Ser[1] 84D4-6;85B6 NC  
Df(3R)p-XT103, ru[1] st[1] e[1] ca[1]/TM3, Sb[1] 85A2;85C1-2 NC  
Df(3R)by10, red[1] e[1]/TM3, Sb[1] Ser[1] 85D8-12;85E7-
F1 
E S 
Df(3R)BSC38, st[1] ca[1]/TM2, p[p] 85F1-2;86C7-8 E  
Df(3R)M-Kx1/TM3, Sb[1] 86C1;87B1-5 S  
Df(3R)T-32, (kni[ri-1]) cu[1] sr[1] e[s]/MRS 86E2-4;87C6-7 NC  
Df(3R)ry615/TM3, Sb[1] Ser[1] 87B11-13;87E8-
11 
NC  
Tp(3;Y)ry506-85C/MKRS 87D1-2;88E5-6 NC  
Df(3R)ea, kni[ri-1] p[p]/TM3, Ser[1] 88E7-13;89A1 NC  
Df(3R)sbd105, p[p] Ubx[bx-1] sr[1] e[s]/TM3, 88F9- NC  
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Ser[1] 89A1;89B9-10 
C(1;Y)1, y[+]; Df(3R)sbd104/TM2, ry[*] 89B5;89C2-7 E NC 
Dp(3;1)P115/+; Df(3R)P115, e[11]/TM1 89B7-8;89E7 NC  
Df(3R)DG2/TM2, red[1] 89E1-F4;91B1-
B2 
NC  
Df(3R)Cha7, red[1]/TM6B, Tb[1] 90F1-F4;91F5 NC  
Df(3R)Dl-BX12, ss[1] e[4] ro[1]/TM6B, Tb[1] 91F1-2;92D3-6 NC  
Df(3R)H-B79, e[*]/TM2 92B3;92F13 NC  
Df(3R)BSC43, st[1] ca[1]/TM2, p[p] 92F7-
93A1;93B3-6 
E  
Df(3R)23D1, ry[506]/TM3, Sb[1] Ser[1] 94A3-4;94D1-4 E S 
Df(3R)BSC55/TM2 94D2-10;94E1-6 S NC 
Df(3R)BSC56, st[1] ca[1]/TM2 94E1-2;94F1-2 NC  
w[1118]; Df(3R)Exel9012, 
P+PBac{XP5.WH5}Exel9012/TM6B, Tb[1] 
94E9;94E13 E E 
w[1118]; Df(3R)BSC137, 
P+PBac{XP5.WH5}BSC137/TM6B, Tb[+] 
95A2-4;95A8-
B1 
NC  
w[1118]; Df(3R)Exel6195, P{w[+mC]=XP-
U}Exel6195/TM6B, Tb[1] 
95A4;95B1 NC  
cn[1]; Df(3R)mbc-30/TM3, Sb[1] 95A5-7;95C10-
11 
NC  
cn[1]; Df(3R)mbc-R1, ry[506]/TM3, ry[*] Sb[1] 
Ser[1] 
95A5-7;95D6-
11 
S S 
w[1118]; Df(3R)Exel9014, 
P+PBac{XP5.WH5}Exel9014/TM6B, Tb[1] 
95B1;95D1 NC  
w[1118]; Df(3R)Exel6196, P{w[+mC]=XP-
U}Exel6196/TM6B, Tb[1] 
95C12;95D8 S NC 
Df(3R)crb-F89-4, st[1] e[1]/TM3, P{w[+m*]=Ubx-
lacZ.w[+]}TM3, Sb[1] 
95D7-
D11;95F15 
NC  
w[1118]; Df(3R)Exel6197, P{w[+mC]=XP-
U}Exel6197/TM6B, Tb[1] 
95D8;95E5 NC  
Df(3R)crb87-5, st[1] e[1]/TM3, Ser[1] 95F7;96A17-18 NC  
Df(3R)slo8/Dp(3;3)Su[8] 96A2-7;96D2-4 NC  
w[1118]; Df(3R)Exel6203, P{w[+mC]=XP-
U}Exel6203/TM6B, Tb[1] 
96E2;96E6 NC  
w[1118]; Df(3R)BSC140, 
P+PBac{XP5.WH5}BSC140/TM6B, Tb[+] 
96F1;96F10 NC  
Df(3R)Espl3/TM6C, cu[1] Sb[1] Tb[1] ca[1] 96F1;97B1 S NC 
Df(3R)Tl-P, e[1] ca[1]/TM3, Ser[1] 97A;98A1-2 NC  
Df(3R)D605/TM3, Sb[1] Ser[1] 97E3;98A5 S S 
w[*]; Df(3R)IR16/TM3, Sb[1] 97F1-2;98A S S 
Df(3R)BSC42, st[1] ca[1]/TM3, Sb[1] 98B1-2;98B3-5 NC  
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w[1118]; Df(3R)3450/TM6B, Tb[1] 98E3;99A6-8 NC  
w[*]; Df(3R)Dr-rv1, ry[506]/TM3, ry[RK] Sb[1] 
Ser[1] 
99A1-2;99B6-11 E S 
Df(3R)L127/TM6; Dp(3;1)B152 99B5-6;99F1 NC  
Df(3R)B81, P{ry[+t7.2]=RP49}F2-80A e[1]/TM3, 
Sb[1]; Dp(3;1)67A 
99D3;3Rt NC  
C(4)RM, ci[1] ey[R]/0 101F1;102F8 NC  
y[1] w[*]; Df(4)O2/In(4)ci[D], ci[D] pan[ciD] 
sv[spa-pol] 
<102C02;102D0
2> 
NC  
y[1] w[*]; Df(4)G/In(4)ci[D], ci[D] pan[ciD] 102E2-7;102E-
F2 
NC  
 
KEY 
NC: no change in phenotype 
S: suppression of phenotype 
E: enhancement of phenotype 
Grayed out: severity score is not significantly different to control  
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Summary 
We developed and characterized in vitro and in vivo models which recapitulate 
key features of VCP mutation-dependent degeneration. Genetic screening of our 
Drosophila model identified four dominant modifiers of toxicity associated with VCP 
mutations: Ube4b, a known binding partner which we found to have altered affinity for 
mutant VCP, and three RNA-binding proteins including TBPH, the Drosophila orthologue 
of TDP-43. We demonstrated that disease-causing mutations in VCP led to a 
redistribution of TDP-43 to the cytoplasm in vitro and in vivo, and that this redistribution 
was sufficient to cause degeneration in vivo. Together our results show that 
degeneration associated with VCP mutations is mediated, in part, by toxic gain of 
function of TDP-43 in the cytoplasm where its redistribution is possibly due to the 
altered binding repertoire of VCP. The results and conclusions presented in this study 
help gain insight into the pathogenesis of VCP-mediated degeneration but also many 
other associated disorders. 
 
Genetic screening of a Drosophila model of VCP mutation-mediated degeneration 
reveals potential pathogenic pathways 
Mutations in the AAA-ATPase, VCP, cause an autosomal dominant disorder that 
includes the variable penetrance of adult-onset proximal and distal muscle weakness 
(clinically resembling inclusion body myopathy; IBM), early onset Paget’s disease of 
bone (PDB) and premature frontotemporal dementia (FTD) (Watts et al. 2004). 
Pathology is characterized by nuclear and cytoplasmic inclusions that are ubiquitin- and 
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TDP-43-positive but VCP-negative (Guinto et al. 2007). TDP-43’s redistribution from the 
nucleus to the cytoplasm also correlates with cellular toxicity. How mutations in VCP 
lead to a disease that affects multiple tissues remains unknown. Previous work modeling 
VCP disease in cell and mouse models has found that expressing mutant VCP 
recapitulates many features of the pathology (Weihl et al. 2007; Custer et al. 2010). We 
have also developed a cell culture model expressing mutant VCP(R155H) and 
VCP(A232E) in HEK293T cells and in mouse primary neuron cultures that exhibited a 
mutation- and time-dependent toxicity that was associated with redistribution of TDP-
43 (Fig 2.3 and S2.3). While the previously published studies have produced models that 
recapitulate features of the pathology associated with VCP mutations, insights into 
potential pathogenic mechanisms have so far focused on a few known individual 
functions of VCP. 
VCP is essential for multiple processes in the cell including many degradative  
pathways including endoplasmic reticulum-associated degradation (ERAD) (Nowis et al. 
2006; Ballar and Fang 2008) and the ubiquitin-proteasome (UPS) and autophagic 
pathways (Wojcik et al. 2006; Tresse et al. 2010) as well as non-proteolytic functions 
including nuclear envelope formation (Hetzer et al. 2001) and homotypic membrane 
fusion during biogenesis of the ER and Golgi apparatus (Uchiyama et al. 2002). Initial 
work focused on ERAD, the best-characterized function of VCP with the hypothesis that 
the ubiquitin-positive inclusions seen in affected tissues were a result of improperly 
degraded misfolded proteins in the ERAD pathway (Weihl et al. 2006). Subsequent 
studies have found that while there is no impairment in ERAD, there is a mutation-
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dependent impairment in autophagy, a functional role only recently ascribed to VCP (Ju 
and Weihl 2010; Tresse et al. 2010). However, the implications of this are unknown. 
Other results of mutant VCP expression have found decreased proteasome activity, ER 
stress and increased markers of apoptosis (Gitcho et al. 2009). These observations could 
be interpreted as results of toxicity within the cell rather than indicative of a pathogenic 
mechanism. However, this work acts to underscore the hypothesis that cellular toxicity 
in VCP-disease may result from the dysfunction of many VCP functions including 
pathways not currently considered within its functional repertoire.  
This unknown differential effect on the VCP functional network including the 
potential for a toxic gain of a novel function due to mutations in VCP, led us to develop a 
tractable disease model in which we could perform unbiased genetic screening in an in 
vivo setting. We developed the first Drosophila melanogaster model of VCP disease by 
expressing wild type (WT) and mutant forms of the gene TER94 that encodes the highly 
conserved VCP orthologue dVCP. Conservation between VCP and dVCP is especially high 
across the N terminus, where many of the disease-associated mutations reside, and all 
known amino acid residues altered in the disease are perfectly conserved (Table 1.1). 
We introduced the R152H and A229E mutations into dVCP, homologues of the R155H 
and A232E mutations. Similar to other models of VCP-mediated disease, we were able 
to recapitulate mutation-dependent degeneration in tissues affected in the disease; the 
brain and muscle, as well as the highly ordered structure of the Drosophila eye (Fig. 2.1, 
S2.1). Drosophila melanogaster is a powerful genetic system in which molecular 
pathways are highly conserved but due to their greater simplicity than humans have 
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proven valuable tools for rapid genetic screening. Using WT and mutant dVCP expressed 
in the Drosophila eye, we performed an F1 genetic screen and identified four dominant 
modifiers; Ube4b, TBPH, xl6 and Hrb27C (Fig. 3.4). The ubiquitin conjugation factor 
Ube4b is one of the many known binding partners of VCP. Together they regulate the 
production of multiubiquitin chains on substrates which targets them for degradation by 
the UPS (Koegl et al. 1999). The three remaining modifiers discovered by the genetic 
screen were all RNA-binding proteins, one of which, TBPH, is the Drosophila homologue 
of TDP-43, a protein found as the major component of inclusions in a spectrum of 
disorders that include VCP disease (Geser et al. 2008). Together these modifiers 
implicate multiple functional pathways potentially underlying VCP-mediated 
pathogenesis. This chapter will aim to discuss the results of the work described in 
Chapters 2 and 3 as well as their impact on the field and the remaining questions still to 
answer. 
 
TDP-43 is a mediator of VCP mutation-related pathogenesis but the mechanism 
remains unknown. 
TDP-43 pathology is a prominent pathological feature in an emerging 
clinicopathalogical spectrum of sporadic and inherited diseases including ALS, FTD-TDP, 
Perry Syndrome and IBMPFD (Neumann et al. 2007; Geser et al. 2009; Salajegheh et al. 
2009). In these diseases, pathological TDP-43 is abnormally hyperphosphorylated, 
ubiquitinated and cleaved to generate C-terminal fragments (Neumann et al. 2006). 
Moreover, TDP-43 is redistributed from its normal nuclear localization to form insoluble 
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cytoplasmic aggregates (Neumann et al. 2007; Geser et al. 2009; Salajegheh et al. 2009).  
TDP-43 contains both nuclear export and import sequences (NES and NLS respectively) 
and undergoes nucleocytoplasmic shuttling (Ayala et al. 2008) potentially playing a role 
in the shuttling of mRNA from the nucleus to the cytoplasm. In addition to the 
redistribution found in the brain and muscle of patients, and cultured cells expressing 
disease-associated VCP mutations, TDP-43 relocalizes to the cytosol in response to 
axonal injury (Moisse et al. 2009). Therefore, it is unclear whether TDP-43 relocalization 
is a mediator of pathology or a physiological response to it. 
 The recent identification of disease-associated mutations in TDP-43 has further 
implicated TDP-43 in disease pathogenesis. In our studies we provide the first evidence 
in vivo that toxic gain-of-function of TDP-43 in the cytoplasm partly mediates the 
degeneration associated with VCP mutations. This is illustrated by the suppression of 
degeneration when endogenous TBPH is depleted in the Drosophila model of VCP 
disease (Fig 2.2B,C) and enhancement of degeneration when TBPH or TDP-43 is 
overexpressed (Fig 2.D, 2.6). We are careful to acknowledge that TDP-43 is likely only 
partially responsible for the toxicity associated with VCP mutations. Other defects, such 
as impairment of autophagy, likely contribute too. We further acknowledge that part of 
the toxicity associated with the redistribution of TDP-43 may be due to a loss of function 
of TDP-43 in the nucleus. We show that when TDP-43 is unable to bind to a known 
target, due to mutations in the binding site or its loss from the nucleus (by reduced 
expression or mutant VCP), the normal splicing repression function is lost (Figure 2.3H-I 
and S2.3G). Together, our studies demonstrate a causative relationship between TDP-43 
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redistribution and disease toxicity but what is the mechanism by which mutations in 
VCP influence the subcellular distribution of TDP-43 and how does this lead to 
degeneration?  
There are many possible mechanisms whereby VCP mutations lead to TDP-43 
redistribution 
In order to understand the pathogenesis of VCP disease we must identify what 
function(s) of VCP is affected and how it is related to TDP-43 localization. We outline 
several possibilities that could underlie the increased nuclear export and/or decreased 
nuclear import of TDP-43. VCP’s primary role is to segregate target proteins from 
molecular complexes. This segregase function is mediated by the ATPase activity, which 
translates ATP hydrolysis into mechanical forces that rotates the outside rim of the 
homohexamer (Rouiller et al. 2002). It has been proposed that VCP’s ability to extract 
ubiquitinated substrates from multiprotein complexes is through these ATP-powered 
conformational changes to extract ubiquitinated substrates from multiprotein 
complexes. Disease-associated mutant VCP proteins are reported to retain a normal 
hexameric structure but exhibit altered communication between the N and D1 domains. 
This could manifest as a disruption in the normal control of the N domain where many 
substrates bind (Fernandez-Saiz and Buchberger 2010) and result in altered removal of 
substrates from multiprotein complexes. TDP-43 is known to associate with 
ribonucleoprotein complexes within the cytoplasm (Freibaum et al. 2010). Evidence of a 
direct physical interaction between VCP and TDP-43 is inconclusive. A recent proteomic 
approach from our lab evaluating TDP-43’s interactome listed VCP as a TDP-43 
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interacting protein and the two proteins were found in complex by co-
immunoprecipitation (Gitcho et al. 2009; Freibaum et al. 2010). However, we have been 
unable to confirm this independently with our own co-immunoprecipitation studies. 
Despite this, it is plausible that VCP activity is necessary for the removal of TDP-43 from 
ribonucleoprotein complexes. Alternatively, the yeast homolog of VCP, cdc48 has been 
found to be essential to ribophagy (Ossareh-Nazari et al. 2010). Impairment of either 
activity could result in progressive cytoplasmic accumulation of TDP-43. A second 
possibility is that VCP is responsible for the nuclear import of TDP-43. Though not a well-
defined role for VCP, it has reported that VCP regulates the nuclear import of the T-cell-
specific adaptor protein in T cell transduction (Marti and King 2005) and is known to 
associate with the adaptor Npl4, a protein originally identified in a yeast screen for 
mutants deficient in nuclear protein import (DeHoratius and Silver 1996; Fabre and Hurt 
1997). By extension VCP may regulate the nucleocytoplasmic shuttling of additional 
proteins, including TDP-43, which mutations may disrupt. Another function of VCP that 
is better characterized is autophagy. Recent discoveries demonstrate that VCP plays an 
important role in autophagy; the maturation of autophagosomes, which disease-
mutations prevent (Ju and Weihl 2010; Tresse et al. 2010). In addition, the accumulation 
of TDP-43 in the cytoplasm that we observe experimentally and in patient tissue, 
mirrors that seen when autophagy is inhibited (Wang et al. 2010). This implies TDP-43 is 
an autophagic substrate and the cytoplasmic accumulation results from a defect in its 
degradation; a pathway regulated by VCP and proven to be impaired by disease-
associated mutations. Further work is needed to evaluate these possibilities and of 
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course, they are not necessarily mutually exclusive. It is possible that redistribution of 
TDP-43 reflects defects in VCP functions that are presently unknown or not considered 
here. As we understand more about the processes that regulate and are regulated by 
TDP-43, especially within the cytoplasm, we will develop an understanding of how it 
interacts with VCP and its functional network. 
TDP-43 mediates toxicity associated with mutations in VCP through a gain of unknown 
function in the cytoplasm 
The results outlined in Chapter 2 demonstrate that degeneration initiated by 
mutations in VCP is mediated in part through a toxic gain-of-function of TDP-43 in the 
cytoplasm. This is consistent with the studies showing that mutations in TDP-43 that 
cause familial ALS promote cytoplasmic mislocalization and cytoplasmic TDP-43 
inclusions (Nonaka et al. 2009; Barmada et al. 2010). Indeed, we show in vivo that the 
recently discovered pathogenic mutation TDP-43 M337V promotes degeneration in the 
Drosophila eye and was accompanied by the redistribution of TDP-43 to the cytoplasm 
(Figure 2.5A and 2.6). We also observed a correlation between the severity of the 
phenotype and the biochemical appearance of abnormal C-terminal fragments (Figure 
2.5, S2.6B). Biochemical analyses of the detergent-insoluble fraction from patient brains 
afflicted with FTD-TDP and ALS demonstrate that accumulated TDP-43 is 
hyperphosphorylated, ubiquitinated and cleaved so that C-terminal fragments 
accumulate in cortical neurons (Arai et al. 2006; Neumann et al. 2006). The effect of 
these post-translational modifications on TDP-43 subcellular localization and 
cytoplasmic-associated toxicity is unclear. In vitro studies to date agree that a 25kDa C-
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terminal fragment generated from caspase cleavage of TDP-43 promotes toxicity and is 
prone to phosphorylation (Hasegawa et al. 2008). However, conflicting reports exist on 
whether these fragments act to redistribute full-length TDP-43 and seed inclusions, or 
cause a change in the biological activity of TDP-43 (Igaz et al. 2009; Zhang et al. 2009). 
Many of the missense mutations in sporadic and familial ALS cluster in the C-terminus of 
TDP-43. Therefore, how this region may promote toxicity needs to be understood. 
Truncation studies in Drosophila are ongoing in our lab to understand if there is a cause-
and-effect relationship between the abnormal species seen in disease, and 
pathogenesis. 
We are intrigued by the possibility that cytoplasmic TDP-43 perturbs some 
aspect of cytoplasmic RNA metabolism.  This is supported by the results from our 
genetic screen where, in addition to TBPH, we also identified xl6 (the Drosophila 
orthologue of human SR protein 9G8) and Hrb27C (the Drosophila orthologue of the 
human hnRNP DAZAP1) as dominant modifiers of mutant VCP toxicity in vivo (Fig. 2.2, 
S2.2, 3.4). TDP-43 is known to interact with many members of the SR protein and hnRNP 
families as well as a network of cytoplasmic proteins involved in translation. Many of 
these interactions are RNA-dependent (Freibaum et al. 2010). Preliminary evidence 
from our lab indicates that RNA-binding may be integral to the toxicity seen when TDP-
43 is specifically localized to the cytoplasm. Further work is needed to understand the 
contribution of altered RNA metabolism to VCP mutation-dependent toxicity. The 
notion of a defect in RNA metabolism underlying disease is not new. There is a growing 
list of RNA-binding proteins that cause neurodegenerative disease either through 
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mutations to RNA-binding proteins or through mutations that impair their function 
(Cooper et al. 2009; La Spada and Taylor 2010). The downstream consequences are not 
well understood but it is possible that altered RNA metabolism could lead to toxicity 
through multiple mechanisms including, but not limited to: production of toxic RNA 
species, production of toxic/degradation-proof proteins, and the overproduction of 
proteins or production of alternative forms of proteins that lead to downstream 
network changes in the cell. The extent to which perturbation in RNA metabolism 
contributes to TDP-43 proteinopathies in general and IBMPFD in particular will be 
understood as the field moves forward. 
 
The discovery of Ube4b as a dominant modifier of VCP mutation-dependent toxicity 
indicates an altered binding profile of VCP 
 In addition to TDP-43, 9G8 and DAZAP1, we also identified Ube4b as a dominant 
modifier of VCP-mediated degeneration. Similar to the three RNA-binding proteins, 
knockdown of Ube4b expression suppressed the degenerative phenotype of dVCP 
R152H while exogenous expression enhanced (Fig. 3.4 and 3.5). Ube4b is a highly 
conserved ubiquitin-binding protein that binds to VCP and extends ubiquitin chains on 
proteins to target them for degeneration (Koegl et al. 1999). However, what role does 
Ube4b play in pathogenesis? Is this role related to Ube4b-specific pathways or is its 
identification as a modifier indicative of a more general defect related to VCP? Many 
diverse cellular functions of VCP are controlled by co-factors that recruit ubiquitinated 
substrates to VCP and regulate their fate, often by altering their ubiquitination state 
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(Rumpf and Jentsch 2006; Schuberth and Buchberger 2008). The discovery of the 
modifying effects of a VCP adaptor involved in ubiquitination of substrates could 
indicate an altered adaptor profile of VCP and/or an altered ubiquitination profile of 
cellular proteins. This could potentially impact multiple cellular activities. 
Mutations in VCP may cause myopathy through the accumulation of Unc45b  
 One of the specific protein targets of the VCP-Ube4b complex is the muscle-
specific chaperone Unc45b (Janiesch et al. 2007). Dysregulation of Unc45b leads to 
defects in myofibrillogenesis in multiple model systems (Janiesch et al. 2007; 
Wohlgemuth et al. 2007). By regulating the steady state levels of Unc45b, WT VCP plays 
an important role in myofibrillogenesis. Disease-causing mutations in VCP have been 
shown to stabilize Unc45b levels in vitro and in vivo implying this as a contributing factor 
to myopathy (Janiesch et al. 2007; Custer et al. 2010). Though not yet examined in our 
Drosophila model of VCP-mediated degeneration, the increased levels of Unc45b are 
consistent with a mechanism in which overactive myosin remodeling contributes to the 
loss of sarcomere integrity that we observed by TEM (Fig. S2.1F). Therefore, the 
contribution of the VCP-Ube4b-Unc45b pathway to the myopathy associated with VCP-
mutations is worth further investigation. This provides a rich avenue as many of 
Unc45b’s downstream partners in myofibrillogenesis have been identified. Investigation 
into associated chaperones, Hsp90 and CHIP, as well as other factors involved in 
myofibrillogenesis could aid in understanding myopathies which display disorganized 
sarcomeric structure including the myopathy associated with mutant VCP. However, this 
muscle-specific change does not apply to the pathogenesis seen in other affected 
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tissues of patients with VCP mutations. A significant challenge in VCP-disease research is 
to understand the contribution of individual perturbations caused by VCP mutations to 
tissue-specific disease manifestations. 
The accumulation of ubiquitinated targets with mutations in VCP may reflect a defect in 
VCP-Ube4b’s basic role in the oligo-ubiquitination of substrates 
 The accumulation of Unc45b with mutations in VCP is not an applicable 
pathogenic mechanism for all affected tissues but it may indicate an alteration of VCP-
Ube4b’s basic function. Together VCP and Ube4b regulate the oligo-ubiquitination of 
substrates, capping the number of ubiquitin moieties to the minimum threshold 
required for recognition by the proteasome (Richly et al. 2005). VCP is thought to 
regulate the length of the polyubiquitin chains, biasing the reactions to four to six 
ubiquitins, as opposed to the longer chains that occur in its absence. It is possible that 
mutations in VCP abrogate its ability to cap the ubiquitin chains, leading to an 
accumulation of hyperubiquitinated substrates. TDP-43 pathology (where TDP-43 is 
itself highly ubiquitinated) is accompanied by ubiquitin-positive inclusions. This implies 
that proteins are not degraded efficiently and aggregate. The appearance of these 
inclusions is thought to indicate an advanced stage of the disease as they are not 
present in primary myoblasts from patients (Hubbers et al. 2007). In VCP disease it is 
possible that the accumulation of ubiquitinated targets (including TDP-43 and Unc45b) 
reflects the aberrant elongation of polyubiquitin chains on substrates effectively 
masking them from preferential degradation. Investigation into the ubiquitin profile of 
the cell in the context of VCP mutations will be continued in the Taylor lab. It is of 
98 
particular interest to investigate whether VCP and Ube4b are directly involved in the 
ubiquitination of TDP-43. 
Alteration in the binding affinity of Ube4b for mutant VCP may indicate a general change 
in the binding profile of VCP  
We discovered through our unbiased screen that mutations in VCP alter its 
functional relationship with Ube4b, one of its binding partners. Mutations in VCP were 
found to increase the steady state levels of Unc45b, a target of the VCP-Ube4b complex, 
but no comment was made to the effect of VCP mutations on Ube4b binding (Janiesch 
et al. 2007). Our study revealed an increased binding of mutant VCP to Ube4b (Fig. 3.6). 
Further evidence of this has also been provided by a collaborator’s yeast two-hybrid 
study (Spinnette and Taylor, unpublished observations). However, this is in contrast to 
work recently published in which the authors claim that expression of disease-
associated VCP mutants lead to a reduced binding of Ube4b (Fernandez-Saiz and 
Buchberger 2010).  Importantly, it was reported in their study that increasing expression 
of other known adaptors affected the binding of Ube4b to mutant VCP presumably 
through competition for sites on the VCP hexamer. Our study overexpressed Ube4b, 
thereby eliminating competition for binding. High resolution approaches including 
crystallography studies, surface plasmon resonance spectroscopy and cryo-electron 
microscopy are among the techniques being employed in our lab and in collaborators’ 
labs to evaluate disease-specific changes in VCP’s binding ability to Ube4b.  
Conflicting reports of increased binding to mutant VCP also exist for other known 
adaptor proteins: ataxin-3 (curiously a substrate for VCP-Ube4b-regulated degradation , 
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p47 and Npl4 (Fernandez-Saiz and Buchberger 2010). However previous studies found 
no change in the binding of these adaptor proteins with mutant VCP (Hubbers et al. 
2007) (Taylor lab unpublished results). All of the studies differed in experimental 
conditions. A comprehensive and unbiased global proteomic approach to understanding 
the changes to VCP’s binding profile in vivo is needed. 
 
Concluding Remarks 
The increased steady-state levels of Unc45b observed in patient and mouse 
model muscles, indicate the loss of a known VCP-Ube4b-related function. Similarly we 
have proposed that the accumulation of redistributed cytoplasmic TDP-43 may be due 
to the loss of a VCP function related to TDP-43’s recycling in the cell.  In our studies, loss 
of Ube4b and TBPH (and other RNA-binding proteins) proved beneficial and suppressed 
the toxicity associated with mutant-VCP expression in the fly (Fig. 3.4). Concomitantly, 
overexpression of Ube4b and TBPH/TDP-43 enhanced the mutant VCP degenerative 
phenotype (Fig. 3.5, 2.2D, 2.6). When we assessed the binding relationship in vitro when 
both mutant VCP and Ube4b were in excess, we observed an increased affinity for 
Ube4b to mutant VCP (Fig. 3.6). A recent study suggests that mutations in VCP result in 
altered transmission of conformational changes from the D1 to the N domain of VCP, 
where Ube4b and other adaptors are known to bind (Morreale et al. 2009; Fernandez-
Saiz and Buchberger 2010). These structural rearrangements suggest altered cofactor 
interactions, the extent of which requires further investigation. Altogether, these results 
support the hypothesis that mutant VCP becomes trapped in unproductive complexes. 
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Due to the hierarchical control of many protein pathways exhibited by VCP, any change 
in the binding profile, and consequently the functional output of its associated 
complexes, could have differing effects on a multitude of cellular pathways. This 
includes the toxic gain of function in some downstream pathways, such as myosin 
remodeling or a toxic cytoplasmic function of TDP-43. Preventing these complexes from 
forming, through the loss of the adaptor protein, could allow alternative pathways to 
restore the homeostasis. This would explain the beneficial effect of reducing the 
expression of Ube4b and TBPH that we saw in our fly model. Further work is required to 
understand: what complexes are preferentially formed by mutant VCP, what pathways 
are affected and what is their relative importance to pathogenesis in the different 
tissues. Answering these questions will ultimately identify therapeutic targets. Our 
development of tractable models of VCP disease has provided excellent resources in our 
further research for the pathogenic mechanism related to mutations in VCP.  
Our research has also provided new focus to understanding other 
proteinopathies. For example, TDP-43 pathology classifies a spectrum of 
clinicopathological disorders. In those disorders where TDP-43 pathology is a major 
feature, we may extend our finding that TDP-43 mediates degeneration through a toxic 
gain of function in the cytoplasm to them. With the finding that other RNA-binding 
proteins also mediate toxicity, these disorders may represent a new subclass of 
neurodegenerative diseases where RNA metabolism underlies pathogenesis. As 
mentioned above, there is a high frequency of inherited neurodegenerative diseases 
caused by mutations that impair RNA metabolism, either through mutations in RNA-
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binding proteins or through mutations that impair the function of RNA-binding proteins 
(Cooper et al. 2009; La Spada and Taylor 2010). Many diseases, including those where 
TDP-43 is considered a secondary feature of pathology, share the presence of 
ubiquitinated inclusions. VCP has been detected in a small proportion of these disease-
defining inclusions (Hirabayashi et al. 2001; Mizuno et al. 2003; Ishigaki et al. 2004). VCP 
regulates a number of ubiquitin-dependent proteolytic functions. The discovery of 
Ube4b as a modifier of VCP toxicity underscores the importance of understanding the 
pathways by which these aggregated proteins are ubiquitinated. In addition, the notion 
that toxicity may result from the altered relationship of VCP to a known adaptor is 
intriguing. Some diseases result from mutations in VCP’s known adaptors. For example, 
mutations in ataxin-3 cause Machado-Joseph’s disease. Interestingly, VCP is also known 
to bind to the Ube4B portion of the chimeric protein Slow Wallerian degeneration 
protein (WldS) (Morreale et al. 2009). Insights from these diseases may also be 
applicable to VCP-disease now that a common link has been found.  The extent to which 
perturbation in these functions contribute to proteinopathies in general, and IBMPFD in 
particular, will be fascinating to learn as the field moves forward. 
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